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Abstract 
 
 Bordetella pertussis is the causative agent of whooping cough, a highly 
contagious infection of the upper respiratory tract that can lead to particularly severe 
disease in infants and young children, including death.  A whole cell vaccine was 
introduced in the 1940s leading to a rapid decline in the number of cases; however 
adverse events from the vaccine led to the development and release of a safer acellular 
vaccine in the 1990s.   Since the introduction of the acellular vaccine, pertussis cases 
began to rise.   The past few years have seen a particularly large resurgence in cases; in 
2012 the number of reported cases in the United States was the highest since 1955.  
Reasons for this resurgence are not entirely clear.  As a large proportion of cases are in 
fully vaccinated individuals, we hypothesized that interactions with host microbiota 
through coaggregation interactions may play a role in who gets infected.    We further 
hypothesized that vaccination selected for B. pertussis strains without the antigens 
included in the vaccine. 
 To explore the ability of B. pertussis to coaggregate with common commensals of 
the nasopharynx we developed a high-throughput method for its detection.  I applied 
this method to screen for coaggregation between 10 B. pertussis strains with 20 
nasopharygeal commensal strains. We also used whole genome sequencing and 
phylogenetic analysis of 100 B. pertussis isolates randomly selected from 8 vaccination 
time periods to test whether vaccination produced a bottleneck in the B. pertussis 
genome. 
  There was apparent coaggregation between B. pertussis and strains of H. 
influenzae, P. aeriginosa, S. aureus, S. pyogenes, and S. pneumoniae; however visual 
examination using the FlowCam™ runs and confocal microscopy suggested induction of 
 xv 
 
autoaggregation in B. pertussis by S. aureus and P. aeruginosa, and no interaction 
between B. pertussis and the other strains.  By inducing autoaggregation in B. pertussis, 
S. aureus and P. aeriginosa may be able to prevent B. pertussis from colonizing the host.  
Analysis of the genetic sequence data suggests that pre-vaccine era isolates are distinct 
from post-vaccination strains (p<0.0001) and that B. pertussis underwent a bottleneck.  
 1 
 
Chapter 1. Introduction 
1.1      Bordetella pertussis: Clinical Symptoms and Changing Epidemiology 
 Pertussis infection (whooping cough) is caused by the bacterium Bordetella 
pertussis, a Gram negative coccobacillus that attaches to the ciliated epithelial cells of 
the nasopharynx (Melvin et al. 2014).  Pertussis is a highly contagious infection of the 
upper respiratory tract and is characterized by severe episodes of paroxysmal coughing 
followed by an inspiratory whoop (Council of State and Territorial Epidemiologists 
2010).  Pertussis is clinically defined as a cough illness that lasts more than two weeks 
and includes one or more of the following symptoms: paroxysms of coughing, 
inspiratory whoop, posttussive vomiting, and – for infants under one year - apnea  
(Centers for Disease Control and Prevention 2016).  The natural history of clinical 
pertussis has three separate stages.  The first stage, catarrhal, typically begins with 
general upper respiratory tract symptoms (rhinorrhea and cough).  One to two weeks 
later the paroxysmal stage begins and includes severe coughing episodes typically 
ending in an inspiratory whoop.  The final stage, the convalescent stage, occurs 2-4 
weeks later and is characterized by improvement of symptoms, although a cough can 
remain for one to three months (Halperin SA 2012).  Individuals of all ages can be 
infected, but adults and adolescents typically have milder cases or may be 
asymptomatic, whereas infection in infants can lead to severe complications and can be 
fatal (Halperin SA 2012).  
 A whole cell pertussis, diphtheria, and tetanus combination vaccine (DTP) was 
introduced in the United States in the mid-1940’s (Centers for Disease Control and 
Prevention 2016).  Since widespread vaccination began in North America, the number of 
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reported cases has decreased by over 90% (Halperin SA 2012).  Due to concerns over 
reactogenicity with the whole cell vaccine, an acellular vaccine (DTaP) was introduced in 
the United States and licensed for the fourth and fifth doses of the childhood 
vaccinations series in 1991 and for the entire  five dose series by 1997 (Schmidtke et al. 
2012).  An acellular adolescent and adult booster (Tdap) was recommended in 2005. 
 In the pre-vaccine era, pertussis infection was common causing an average of 
178,000 reported cases per year and affecting mostly children aged 1-9 years (Figure 1) 
(Centers for Disease Control and Prevention 2016; Melvin et al. 2014).  Following the 
introduction of the whole cell vaccine in the 1940s, the number of reported cases fell to 
approximately 17,000 annually during 1950-1990 (Figure 1) (Centers for Disease Control 
and Prevention 2016).   A resurgence in reported cases coincided with the introduction 
of the acellular vaccine in 1991 and by 2012, the number of reported cases increased to 
nearly 42,000 per year (Figure 1) (Centers for Disease Control and Prevention 2016).  
The epidemiology since the resurgence has changed substantially: with pertussis 
infection being more common in infants (<1 years) and older children (ages 9-19) 
(Melvin et al. 2014).  Further, cases in older children and adults often occur in fully 
vaccinated individuals.  During a B. pertussis outbreak in California during 2010, 79% of 
the infected children ages 7-10 were fully vaccinated (Winter et al. 2012).  Population 
data from 1996-2010 in Norway found 90% of the cases among those 14 and older were 
fully vaccinated (Lavine et al. 2010).  Although the whole cell vaccine appears to provide 
a longer duration of immunity, both the whole cell vaccine and the acellular vaccine fail 
to induce sterilizing immunity (Locht 2016; Warfel et al. 2014; Witt et al. 2012).    
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Figure 1.1  Reported National Notifiable Disease Surveillance System (NNDSS) 
reported pertussis cases:  1922-2014 
 
 
 Reasons for this resurgence are not entirely clear.  Some current hypotheses 
include:  waning immunity over time following vaccination or infection (Tan et al. 2005; 
Wearing & Rohani 2009), antigenic divergence of circulating strains in response to 
selective pressures from vaccines (Mooi et al. 2001), decreased vaccination rates (Omer 
et al. 2009), variable vaccine efficacy (Crowcroft & Pebody 2006; Ntezayabo et al. 2003), 
age-structured contact patterns (Rohani et al. 2010), and acellular vaccines failing to 
prevent transmission by protecting against disease but not infection leading to an 
increase in asymptomatic carriage (Warfel et al. 2014).  Lending further support to 
acellular vaccines resulting in asymptomatic carriage, in a secondary analysis of an 
acellular vaccine efficacy trial, researchers found that while the vaccine did prevent the 
disease, it did not protect against infection or colonization (Storsaeter et al. 1990).  In 
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addition, an antibody study in a vaccinated cohort of healthy one-year olds found 5-10% 
had evidence of recent B. pertussis infection although few clinical cases were recognized 
in the community at the time (von Linstow et al. 2010).  
1.2      Pertussis Vaccine and Antigenic Divergence 
 The current acellular pertussis vaccines contain five B. pertussis components:  
pertussis toxin (ptxP and ptxS1), filamentous hemagglutinin (fha), fimbrial agglutinogens 
2 and 3 (fim2 and fim3), and pertactin (prn) (Decker & Edwards 2000) (Figure 1.2).  The 
two main manufacturers of the acellular vaccine used in the United States are 
GlaxoSmithKline and Sanofi Pasteur.  The strain used for the manufacture of the 
GlaxoSmithKline vaccine in the United States is Tohama 1, a strain first isolated in Japan, 
which has an allelic variant profile of prn (1)-ptxP(1)-ptxS1B-fim2(1)-fim3(A) (Schmidtke 
et al. 2012; Bottero et al. 2007). The Sanofi Pasteur acellular pertussis vaccine is 
manufactured from B. pertussis strain 10536 (prn(1)-ptxP(1)-ptxS1D-fim2(1)-
fim3(A))(Bottero et al. 2012) obtained from the Michigan Department of Health 
(Grabenstein 2012).   
 Since the introduction of the acellular vaccine, the most common circulating 
strains in the United States have diverged away from vaccine strain alleles (Table 1.2). 
For example, since 1991 the ptxP3 allele – associated with increased toxin production - 
has become the dominant ptxP allele in the United States replacing the ptxP1 allele 
found in both vaccine strains (Schmidtke et al. 2012; Mooi et al. 2009). Antigenic 
divergence of circulating strains in response to selective pressures from vaccines has 
been observed worldwide (Mooi et al. 2001; Mooi et al. 2009; Bart et al. 2014; Bart et 
al. 2010).  Antigenic divergence of circulating strains away from vaccine strains might 
render the vaccine less effective resulting in an increase in cases.  This has already been 
observed in the Netherlands, where the shift to ptxP3 toxin was associated with an 
increase in pertussis infection notifications (Mooi et al. 2009).     
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Table 1.1 Genotype of vaccine strains, number of circulating alleles, and predominate 
allele in the United States 
 Acellular Vaccine Components 
Sources 
prn ptxP ptxS1 fim2 fim3 
V
ac
ci
n
e
 
St
ra
in
s Tohama 1 genotype 1 1 B 1 A 
(Schmidtke et al. 
2012; Bottero et 
al. 2012) 
10536 genotype 1 1 D 1 A 
(Bottero et al. 
2012; Grabenstein 
2012) 
Number of circulating alleles 2 11 6 2 4 
(Kallonen & He 
2009; Mooi et al. 
2009; Locht 2007) 
Predominate allele in US 2 3 A  B 
(Schmidtke et al. 
2012; Cassiday et 
al. 2000) 
 
1.3      Asymptomatic Carriage 
 Individuals with unrecognized pertussis infections can serve as reservoirs for 
transmission in hospital settings and within families (Conover & Sloan 2010).  While little 
is known about the prevalence of asymptomatic carriage in the absence of vaccination, 
neither the acellular nor whole cell vaccines were able to prevent colonization and 
Figure 1.2.  Acellular vaccine component locations on B. pertussis cellular surface 
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asymptomatic infection as well as natural immunity from a previous infection (Warfel et 
al. 2014).  Using a baboon model for B. pertussis infection, Warfel et al. and found that 
while vaccination with acellular pertussis (ap) protected against severe symptoms, it did 
not protect against colonization (Warfel et al. 2014).  Importantly, vaccinated baboons 
did not clear the infection any faster than naïve animals and could readily transmit B. 
pertussis to their unvaccinated contacts (Warfel et al. 2014).  By comparison, the whole 
cell vaccine induced more rapid clearance in both aP-vaccinated and naïve animals 
(Warfel et al. 2014).  Natural infection completely prevented colonization upon 
secondary infection (Warfel et al. 2014).  Warfel et al. propose that asymptomatic 
infection and subsequent transmission by individuals vaccinated with the acellular 
vaccine could, in part, explain the increase in observed B. pertussis incidence (Warfel et 
al. 2014).  In a study examining the household contacts of 16 infants hospitalized with B. 
pertussis infection, parents and siblings, nearly half of which were asymptomatic, were 
found to serve as an important source of infection (Raymond et al. 2007).     
1.4      Nasopharyngeal Microbiota may Mediate Risk of Pertussis Infection 
The human microbiota is comprised of the ecological community of commensal, 
symbiotic, and pathogenic microorganisms found in and on the human body (Lederberg 
2001).  These organisms can protect the host from potentially invading pathogens 
through both microorganism-mediated direct inhibition and indirectly by enhancing 
host immunity (Buffie & Pamer 2013).  There is some evidence that host microbiota can 
influence the ability of B. pertussis to colonize. Using a murine model Weyrich et al. 
determined that delivering a broad-spectrum antibiotic treatment before B. pertussis 
inoculation reduced the infectious dose from 10,000 CFU to less than 100 CFU and that 
reintroduction of a single Staphylococcus or Klebsiella species was sufficient to inhibit B. 
pertussis colonization in antibiotic-treated mice (Weyrich et al. 2014).  These results 
show that host microbiota can influence host specificity and prevent colonization by B. 
pertussis in mice (Weyrich et al. 2014). We hypothesize that interactions with host 
microbiota are also an important determinant in the ability of B. pertussis to colonize 
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humans.  With a large number of infections occurring in fully vaccinated individuals, 
clearly other factors contribute to who becomes infected.  
B. pertussis might interact with the host microbiota through several mechanisms.  
Bordetella species contain many mechanisms for interbacterial competition including a 
type IV secretion system for secretion of pertussis toxin, bacteriophages, and potentially 
contact-dependent growth inhibition (Weyrich et al. 2014). Coaggregation, the highly 
specific recognition of surface molecules between two genetically distinct bacterial cell 
types, is common among oral bacteria and may be another mechanism through which B. 
pertussis interacts with the host microbiota (Hughes et al. 1988).  Coaggregating 
organisms and multi-species biofilms have many advantages compared to planktonic 
cells such as resistance to antimicrobials, the host immune system, and shear forces, 
and are able to share nutrients (Rickard et al. 2003; Mishra & Parise 2005; Watnick & 
Kolter 2000).   
The ability to coaggregate is important for the development of multispecies 
biofilms, which may allow B. pertussis to persist in the nasopharynx of the host.  Biofilms 
consisting solely of B. pertussis are well documented, but whether it is able to jointly 
form biofilms with other species, particularly nasopharyngeal commensals in human 
hosts, is unstudied (Arnal et al. 2015; Conover & Sloan 2010; Serra et al. 2011; Mishra & 
Parise 2005; Conover et al. 2012).  Coaggregation interactions are likely important for 
adherence and colonization of bacteria to a variety of host surfaces (Kolenbrander 
1988).    It may be that the presence of certain nasopharyngeal commensals is necessary 
for B. pertussis to attach or the presence of certain commensals may actively prevent B. 
pertussis attachment through antagonistic coaggregation interactions.  
 With a large proportion of cases occurring in fully vaccinated individuals, 
interaction with host microbiota may play a deciding factor in who gets infected among 
vaccinated individuals. If B. pertussis is able to coaggregate with nasopharyngeal 
commensals, it might lead to persistence in the nasopharynx.  Persistence in the 
nasopharynx may result in asymptomatic carriage which is common in adolescents and 
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adults (Halperin SA 2012).  Asymptomatic carriage also is believed to be increasing due 
to the acellular vaccine preventing disease, but failing to prevent transmission and may 
be a key component of transmission dynamics (Warfel et al. 2014; Althouse & Scarpino 
2015).  Lastly, the acellular vaccine is targeted against only a few B. pertussis antigens 
and may result in selection of non-vaccine strains resulting in vaccine failure.  Antigenic 
divergence with respect to several of the vaccine components has already occurred 
(Mooi et al. 2001; Bart et al. 2014; Borisova et al. 2007; Schmidtke et al. 2012).    
1.5      Dissertation Aims 
The overall goal of this dissertation is to evaluate some of the hypothesized 
mechanisms leading to the resurgence of pertussis in the United States.  Chapters 2 and 
3 evaluate the role of coaggregation.  To do so, we first developed a high-throughput, 
quantitative method to screen for coaggregation among bacterial species (Chapter 2).  
The method uses optical density in a 96-well plate format to simultaneously assess for 
coaggregation among multiple replicates of a large number of test crosses and then 
confirms these results with a FlowCam™ device for measuring size of particles over time 
in a flowing environment, and confocal microscopy.  In Chapter 3 we apply this high-
throughput screening method to assess for coaggregation between B. pertussis strains 
and common commensals of the nasopharynx.  In Chapter 4, we screen nasopharygeal 
swab samples taken from 519 healthy adults from 115 households in Vinh Thanh, 
Vietnam to estimate of the rate of asymptomatic carriage of B. pertussis.  We also 
screen this collection for co-occurrence of B. pertussis with the nasopharyngeal 
commensals that we found to interact with B. pertussis in Chapter 3. As noted earlier, 
screening for commensals identified a problem with this collection and raised serious 
questions about the validity of the resulting estimates.  Chapter 5 describes results of 
whole genome sequencing and phylogenetic analysis to identify whether vaccination 
resulted in a genetic bottleneck.  The last chapter provides a general summary of the 
knowledge and skills gained through this dissertation work, including a reflection on the 
challenges of inherent variability of coaggregation, finding and obtaining a large 
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collection of isolates for sequencing, using archival collections, and of learning the very 
diverse set of skills necessary to conduct these various studies. 
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2.1 Significance and Impact of the Study  
Coaggregation between bacterial species is integral to multi-species biofilm 
development. Difficulties in rapidly and reproducibly identifying and quantifying 
coaggregation have limited mechanistic studies. This paper demonstrates two 
complementary quantitative methods to screen for coaggregation.  The first approach 
uses a microplate-based high-throughput approach and the other uses a FlowCam™ 
device. The microplate-based approach enables rapid detection of coaggregation 
between candidate coaggregating pairs of strains simultaneously while controlling for 
variation between replicates. The FlowCam™ approach allows for in-depth analysis of 
the rates of coaggregation and size of aggregates formed. 
2.2 Abstract 
This paper describes a high throughput method that relies upon a microplate 
reader to score coaggregation 60 minutes post mixing, and use of a high-speed real-time 
imaging technology to describe the rate of coaggregation over time. The results of 
visual, microplate, and FlowCam™ aggregation scores for oral bacteria Streptococcus 
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gordonii, Streptococcus oralis, and Actinomyces oris, whose ability to coaggregate are 
well characterized, are compared. Following mixing of all possible pairs, the top fraction 
of the supernatant was added to a microplate to quantify cell-density. Pairs were also 
passed through a flow cell within a FlowCam™ to quantify the rate of coaggregation of 
each pair. Results from both the microplate and FlowCam™ approaches correlated with 
corresponding visual coaggregation scores and microscopic observations.  The 
microplate-based assay enables high throughput screening, whereas the FlowCam™-
based assay validates and quantifies the extent that autoaggregation and coaggregation 
occur.  Together these assays open the door for future in-depth studies of 
autoaggregation and coaggregation among large panels of test strains. 
2.3 Introduction  
Coaggregation is defined as the highly specific recognition and adherence of 
different species of bacteria with each other (Kolenbrander 1988; Rickard et al. 2003).  
Coaggregation typically occurs as a consequence of the expression of protein adhesins 
on the cell-surface of one bacterial species, and complementary polysaccharide-
containing receptors expressed on the surface of the other bacterial species 
(Kolenbrander 1988; Rickard et al. 2003).   
Coaggregation interactions are important for the development of multi-species 
biofilms (e.g. dental plaque).  It contributes to biofilm development via at least two 
mechanisms: i) free floating planktonic cells of one species specifically recognize cells of 
another species type and co-adhere to the developing biofilm, and/or ii) bacterial cells 
of a planktonic species recognize and coaggregate with cells of another species within 
an established biofilm community (Rickard et al. 2003; Kolenbrander et al. 2010).  It is 
likely that these interactions are important for adherence and colonization of bacteria to 
a variety of biotic and abiotic surfaces, and provide selective advantages against non-
coaggregated bacterial species contained within a biofilm (Kolenbrander et al. 1990; 
Busscher & Van Der Mei 1995; Burmølle et al. 2006; Kolenbrander et al. 2010). 
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The oral microorganisms Streptococcus oralis, Streptococcus gordonii and 
Actinomyces oris strongly coaggregate and are considered early colonizers in the 
process of dental plaque formation (Kolenbrander 2000).  Early colonizers anchor the 
biofilm to the substratum surface and thereby contribute to recalcitrance of the biofilm 
to removal (Busscher & Van Der Mei 1995). For example, the presence of A. oris greatly 
reduces the ability of the S. oralis to be removed by shear force when compared with 
direct attachment of S. oralis to the pellicle (proteinaceous conditioning film formed on 
the tooth surface) (Busscher & Van Der Mei 1995).    Furthermore, early colonizers 
provide a foundation for other species to adhere, forming a mature biofilm community 
(Busscher & Van Der Mei 1995). Through autoaggregation (aggregation within a single 
species) or coaggregation, organisms can individually and collectively obtain increased 
resistance towards antimicrobials and shear forces, communicate via cell-cell signaling, 
and share nutrients (Kinder & Holt 1994; Watnick & Kolter 2000; Rickard et al. 2003).  
Research using model dental plaque systems has shown nutritionally mutualistic 
relationships occurring between coaggregating organisms (Bradshaw et al. 1994; Palmer 
et al. 2001).  For example, A. oris and S. oralis displayed limited to no growth when 
grown in monoculture with saliva as the nutrient source, but thrived when allowed to 
coaggregate (Palmer et al. 2001). 
Traditionally, coaggregation is assessed using a visual scoring system based on the 
size of the coaggregates and turbidity of the supernatant fluid (Cisar et al. 1979; Gilbert 
et al. 2002; Vornhagen et al. 2013).  However, as visual scoring is only semi-quantitative, 
it is subject to inconsistency and bias in scoring (Busscher & Van Der Mei 1995).  
Another method, measuring the percent change in optical density, provides a 
quantitative assessment and greatly improves reliability and reproducibility.  However, 
current methods are not amenable to screening of larger numbers of samples 
simultaneously (Ikegami et al. 2004; Ledder et al. 2008; Nagaoka et al. 2008; Arzmi et al. 
2015) and these technological insufficiencies have limited the in depth study of 
coaggregation (Katharios-Lanwermeyer et al. 2014).  The ability to include multiple 
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replicates in a single experiment is highly desirable, as there may be strain variations in 
coaggregation requiring multiple crosses to determine if the observed coaggregation 
occurs generally between two species.  Furthermore, because bacterial coaggregation is 
sensitive to a variety of influences including presence of chelating agents 
(Taweechaisupapong & Doyle 2000), temperature (Postollec et al. 2005), growth media, 
and pH (Min et al. 2010), and growth phase of the batch culture cells (Rickard et al. 
2000), high throughput methods would be highly desirable to improve reproducibility of 
results.   
Cognizant of these issues,   we developed a quantitative method for high 
throughput screening for coaggregation among bacterial species. Our high throughput 
method allows for simultaneous analysis of multiple replicates so that experimental 
variation is reduced and possible subjective bias is minimized. This method’s accuracy as 
a preliminary screening tool was validated using confocal microcopy and a recently 
developed approach using FlowCam™ technology (Segaloff et al. 2014).  A FlowCam™ is 
a dynamic imaging particle analyzer that examines fluid through a microscope and 
captures images of the particles as they are pumped through a flow cell via a computer 
controlled syringe pump.  Specifically, a FlowCam™ characterizes the particles using a 
variety of measurements such as area-based diameter.  It has been used in a variety of 
different industries including aquatic research, algae technology, waste management, 
pharmaceutical, and oil and gases for purposes such as monitoring algae for biofuels, 
quantifying protein aggregates in pharmaceuticals, and analyzing drilling products 
(http://www.fluidimaging.com/).  In practice, the high throughput method can be used 
to screen a large panel of test strains for potential coaggregation.  Ideally, strains giving 
a positive result with the high throughput method would then be tested further using 
either confocal microscopy or FlowCam™. 
Without a high throughput, quantitative method for assessing coaggregation, it is 
difficult to explore the importance of coaggregation for the development of biofilms.  A 
better understanding of coaggregation can provide a deeper knowledge of how 
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organisms interact and biofilms form.  For example, the presence of biofilms can result 
in the corrosion of sewer pipes.  An improved understanding of if and how organisms 
coaggregate in these biofilms could help in developing strategies to reduce the 
detrimental effects of species in biofilms on pipe surfaces (Jensen et al. 2016).  A high 
throughput screening method would also be of interest to the dental research 
community as identifying coaggregation between oral bacterial species (beyond those 
already known) could be an important step in developing a fuller understanding of 
dental plaque development (Kolenbrander et al. 1990).  Coaggregation may also be an 
important mechanism through which pathogens interact with the host microbiota.  
Younes et al. demonstrated a rapid anti-pathogen effect of probiotic lactobacilli with 
toxic shock syndrome toxin 1-producing Staphylococcus aureus strains as a result of 
coaggregation (Younes et al. 2012). High throughput studies of coaggregation between 
organisms could be useful in identifying probiotic species.  
2.4 Results and Discussion: 
2.4.1 High throughput quantitative method increases validity and reliability of 
results 
 Three strains of oral bacteria were used:  Streptococcus oralis 34, Streptococcus 
gordonii DL1, and Actinomyces oris T14V.  S. gordonii is a primary colonizer in dental 
plaques and was previously found to coaggregate with both A. oris T14V and S. oralis 34 
(Cisar et al. 1979).  All possible pairwise combinations of these three strains were tested, 
resulting in six potential coaggregative or autoaggregative pairings.  Coaggregation was 
first assessed in a low throughput format and scored using the visual scoring system 
developed by Cisar and colleagues (Cisar et al. 1979).   As shown in Figure 1A, the 
maximum visual coaggregation (score = 4) is easily distinguished from no coaggregation 
(score = 0), but visual intermediate scoring is more subjective and as a consequence is 
less reproducible.      
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Using the microplate-based approach with OD 620 nm, it was determined that S. 
gordonii DL1 + A. oris T14V, S. oralis 34 + A. oris T14V, and S. oralis 34+ S. gordonii DL1 
all strongly coaggregated (Figure 1B).  No autoaggregation was detected for S. oralis 34 
or S. gordonii DL1.  Some autoaggregation was observed for A. oris T14V, although the 
OD did not differ significantly from that of non-autoaggregating strains.   
Within each micro-plate run, pairs were assayed in triplicate.  The average 
coefficient of variation (standard error / mean) for the triplicates was 14% with a 
median of 9%.  The coefficient of variations differed by specific crosses with 
autoaggregation by A. oris being the most variable (ranging from 1-66%).  An increase in 
the coefficient of variation for coaggregation was also observed when A. oris was a 
component of a coaggregating pair.  
Many factors contribute to between run variations:  bacteria are harvested from 
separately grown batch cultures, which may differ slightly in length of growth time, 
exact nutrient content and pH of media, pH of buffers used for washing and re-
suspension, number of times strain has been passaged before current growth, and 
natural biological variation.  To minimize these variations, bacteria of a given species 
were harvested from the same batch culture, although some variation might remain due 
to the slight variations in timing between admixture and measurement, and true 
biologic variation in the amount of autoaggregation occurring within each species of a 
given candidate coaggregative pairing.  
Between run and within run variation highlight the need for multiple replicates of 
each candidate coaggregative pair in addition to replicates of each strain on its own (to 
assess autoaggregation) within a single run.  This is easily possible using the high-
throughput 96-well plate method.  Quantitatively comparing coaggregative and 
autoaggregative behavior within a single run also enables more accurate assessments of 
coaggregation by controlling for any autoaggregation that may occur, and multiple 
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replicates of all strains and strain pairs allow for construction of confidence intervals 
around the mean OD value for a given strain or strain pair. 
2.4.2 FlowCam™ Technology can measure particle sizes and quantify rate of 
coaggregation 
 FlowCam™ technology was used to validate the high-throughput 96-well plate 
system, providing an in-depth analysis of the rates of coaggregation, and visual and 
quantitative assessment of the size of aggregates formed (Segaloff et al. 2014).  The 
average particle size per minute increased over time for all three coaggregative pairings 
(Figure 2).  By minute three (two minutes post-mixing) all coaggregating strains 
experienced a statistically significant increase in average particle area per minute as 
calculated using area-based diameter.  Strong coaggregation occurred when S. gordonii 
and A. oris were combined, with particles averaging 212 µm2 per minute and reaching as 
large as 3,800 µm2 in area.  The coaggregation between S. oralis and S. gordonii was not 
as strong.  Particle sizes averaged 122 µm2 by the final minute of data collection and 
reached a maximum area of approximately 2,950 µm2, but many cells did not 
coaggregate and remained in suspension.  This variation in coaggregation between this 
pair resulted in large confidence intervals around each time point.  S. oralis and A. oris 
coaggregated strongly with particle sizes averaging 215 µm2 in area by minute two and 
reaching sizes as large as 3,180 µm2.  In the autoaggregation assays, the average area of 
A. oris particles (83 µm2) was significantly larger than those of S. oralis (35 µm2) and S. 
gordonii (51 µm2), indicating strong autoaggregation in this species.  Here, the use of 
FlowCam™ allowed for quantification of rates of coaggregation and measurement of the 
particle size associated with coaggregation.  Results from FlowCam™ correlated well 
with the results of the high throughput screen, with coaggregation indicated by 
increases in particle size over time following the addition of the second organism and 
autoaggregation indicated by larger particle sizes.  FlowCam™ was more useful for 
detecting autoaggregation than the high throughput screening method on its own, 
which did not show a statistically significant difference between autoaggregating and 
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non-autoaggregating strains.  These results validate the use of the high throughput 
method as an initial screening step to be followed up with a more confirmatory assay 
such as FlowCam™ or confocal microscopy. 
2.4.3 Confocal microscopy confirms presence of coaggregation   
As a further confirmation, the strains were stained using Syto-9 (green) or Syto-61 
(red) nucleic acid stains before crossing them for coaggregation, and then visualized 
using a confocal microscope (Figure 3).  Confocal microscopy images confirmed that S. 
oralis and S. gordonii do not autoaggregate (Figure 3, A and C).  Visualization of A. oris 
alone confirmed strong autoaggregative behavior (Figure 3B).  This was not immediately 
apparent from initial absorbance readings from the high throughput screening method 
because autoaggregation was not followed by immediate sedimentation (Figure 1B).  
This finding is consistent with previous reports. Koop and colleagues showed 
autoaggregation without associated sedimentation could be missed by 
spectrophotometry (Koop et al. 1989), highlighting the importance of using a 
combination of methods for detection.  The high-throughput 96-well plate method is 
most appropriately applied as a screen for potentially coaggregating pairs from a large 
pool of candidates.  Potentially coaggregating pairs should be further evaluated using 
FlowCam™ or confocal microscopy, ideally both.  Moreover, if coaggregation is 
suspected, autoaggregation should be ruled out.  
 S. oralis + S. gordonii showed moderate coaggregation (Figure 3D) while S. 
gordonii + A. oris (Figure 3E) and S. oralis + A. oris (Figure 3F) showed strong 
coaggregation.  S. oralis and S. gordonii appeared to coaggregate in a more even 
manner, suggesting absence of autoaggregation within the two species (Figure 3D), 
while S. oralis + A. oris and S. gordonii + A. oris showed clumps of the same color (red or 
green) indicating strong autoaggregative behavior by A. oris (Figure 3, E and F).  
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2.5 Summary  
Focusing on the interactions between three well-documented coaggregating 
strains of oral bacteria, we demonstrated that coaggregation can be quantified, and the 
kinetics of coaggregation and the size of coaggregates formed can be measured. The 
microplate-based assay enables high throughput screening to identify potentially 
coaggregating strains, whereas the FlowCam-based assay validates and quantifies the 
extent that aggregation and coaggregation occur.  In the absence of FlowCam™, or in 
combination with its use, confocal microscopy is a useful tool for confirming the 
presence or absence of coaggregation following screening of a large panel of strains 
with the high throughput method.  Together these assays open the door for in-depth 
studies of aggregation and coaggregation among large panels of test strains.  
2.6 Materials and Methods: 
2.6.1 Growth Conditions 
S. oralis 34 and S. gordonii DL1 were incubated aerobically with CO2 at 37°C in 
Schaedler’s broth for 24 hours.  A. oris T14V was incubated aerobically with CO2 at 37°C 
in Brain Heart Infusion broth for 48 hours.  Cells were harvested from batch culture 
through centrifugation for 12.5 minutes at 3,000 X g and then washed 3 times in 
coaggregation buffer (Cisar et al. 1979; Rickard et al. 2000).  After each centrifugation 
step, the supernatant was discarded and the pellet was re-suspended in coaggregation 
buffer.  The washed pellets were then suspended in coaggregation buffer to achieve an 
optical density at 600 nm of 1.5 (±0.1).      
2.6.2 Coaggregation and Autoaggregation assays 
Coaggregation and autoaggregation were first assessed using a visual 
coaggregation assay developed by Cisar et al. where visual scores ranged from 0 (no 
visible aggregates in the suspension) to 4 (large aggregates form and settle leaving a 
clear supernatant) (Cisar et al. 1979).  To assess coaggregation between two strains, 200 
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µl of each bacterial suspension were combined in a glass culture tube.  To assess 
autoaggregation 400 µl of the single bacterial suspension as placed in a glass culture 
tube.  The culture tubes were then vortexed for ten seconds and rolled gently for an 
additional 30 seconds (Rickard et al. 2000). Each pair was assayed in triplicate.    
Samples were allowed to sit 60 minutes to let coaggregates settle to the bottom 
of the tube.  Any changes in visual coaggregation score following the 60-minute time 
period were documented.  This endpoint was selected after initial testing of the 
supernatant at 30 minute time intervals over 3 hours; 60 minutes was ideal for good 
separation between coaggregating and non-coaggregating strains.  One hundred 
microliters of supernatant were removed from each sample and placed in a 96 well flat-
bottom plate.  Absorbance of the supernatant was measured at 620 (A) using a 
PerkinElmer 2030 workstation (PerkinElmer Life and Analytical Sciences, Turku, Finland).  
Mean OD and associated 95% confidence intervals were calculated over all trials for 
each of the strain pairs and for each strain alone.   Because strains were set to the same 
optical density (1.5) before they were combined, an expected value for the combined 
pair was calculated based on the average experimental OD of the two components.  The 
mean OD, 95% confidence interval, minimum and maximum for each pair was then 
compared with the calculated expected value for the pair.  Coaggregation was 
suspected when the expected value was above the upper limit for the 95% confidence 
interval and was considered when the mean OD was below the expected value.   In all 
cases meeting these criteria, further screening was conducted using FlowCam™ and 
confocal microscopy. 
As an additional visual test of autoaggregation and coaggregation between strains, 
300 μl of each bacterial suspension in coaggregation buffer were stained with either 
Syto-9 (green: Excitation:  488, Emission: 503) or Syto-61 (red: Excitation: 561, Emission: 
645) nucleic acid stains (Invitrogen, Carlsbad, CA, USA).  Each bacterial suspension was 
incubated for 30 minutes at room temperature to allow staining of the cells. Cells were 
washed three times with coaggregation buffer and collected by centrifugation, as 
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mentioned above. Each bacterial strain was re-suspended in coaggregation buffer and 
combined for coaggregation. For autoaggregation studies, Syto-9 and Syto-61 stained 
cells of that species were mixed together.  Twenty microliters of each sample were 
added to the slide and viewed under the microscope.  The entire droplet was scanned 
and a minimum of three representative fields of view were captured for each pair and 
for each strain alone using Leica confocal laser scanning microscopy (CLSM, SPE, Leica, 
IL, USA) with a HCX PL APO 40X/0.85 CORR CS objective.  Staining and microscopy were 
repeated twice to ensure consistency of results.”  Once the microscopy images were 
taken, the image files were rendered using Imaris (Bitplane, Zurich, Switzerland) 
computer imaging software.   
2.6.3 FlowCam™ Imaging and Quantification of Coaggregation  
To confirm the results of our findings, coaggregation was quantified using 
FlowCam™ technology (Fluid Imaging Technologies, ME, USA).  S. oralis 34, S. gordonii 
DL1 and A. oris T14V were harvested from batch cultures and washed as described 
above.  The washed pellets were re-suspended in coaggregation buffer to achieve an 
optical density of 1.0 (±0.1) at 600 nm.  Prior to loading the cells into the FlowCam™ 
device, cell suspensions were further diluted 5X in coaggregation buffer to prevent 
clogging of flow cell.  The first species was added to the device and was pumped 
through until it reached the flow cell.  Data collection began once the Olympus UPlanFL 
N 10X/0.30 objective was successfully focused on the flowing particles.  The second 
species was added to the vessel containing the first species and gently mixed 1 minute 
after initiation of data collection.  FlowCam™ was run for 10 minutes at a flow rate of 
0.3 ml/min with images acquired at a rate of 10 frames per second.  Flash duration was 
set to 8 µSec.   Particle size was measured using area based diameter (ABD) and a 
particle filter of 5 to 10000 μm.  Visual spreadsheet software was used for data 
collection.  A minimum of 5 FlowCam runs was conducted for each pair with similar 
results. 
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Figure 2.1. (A) Test crosses of pairwise combinations of S. gordonii, S. oralis, and A. oris with 
associated visual coaggregation score based on methodology by Cisar et al. 1979.  (B)  Mean 
Optical Density (620 nm) of supernatant with associated 95% confidence intervals of test 
crosses. 
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Figure 2.2.  Change in average particle area (µm) per minute during 10 minute time period 
with associated 95% confidence intervals calculated from number of particles scanned per 
minute for potential (A) coaggregating (S. gordonii + A. oris, S. oralis + S. gordonii, S. oralis +A. 
oris) and (B) autoaggregating (S. gordonii, A. oris, S. oralis) pairs as measured with the 
FlowCam™ device.  Calculations were based on an average of 2,009 particles per minute 
(median = 707, maximum = 5,867, minimum = 24). 
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Figure 2.3.  Visualization of selection bacterial pairings using confocal microscopy.  Confocal 
microscopy images are represented in the x-y plane. Nucleic acid stains syto-9 (green) and 
syto-61 (red) was used to detect autoaggregation and coaggregation of oral microbes. Bars 
represent 40 μM. 
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 Interactions between B. pertussis and other Common Nasopharyngeal Chapter 3.
Commensals 
 
3.1      Abstract 
 Bordetella pertussis infection can result in severe morbidity and even mortality in 
unvaccinated infants and young children, but infection in vaccinated adolescents and 
adults is often asymptomatic or results in milder symptoms such as a prolonged cough.  
Asymptomatic carriers are reservoirs for infection and help maintain ongoing 
transmission.  In recent years, the majority of cases have been in fully vaccinated 
individuals.  We hypothesized that coaggregation between B. pertussis and members of 
the host microbiota might be an initial step in B. pertussis colonization of the 
nasopharynx.  Whether B. pertussis coaggregates is unknown.  We tested whether B. 
pertussis coaggregates with common commensals  of the human oropharynx (10 strains 
of B. pertussis and 20 nasopharyngeal commensal test strains including H. influenzae, S. 
pneumoniae, N. meningitidis, and S. aureus.) using a high-throughput screening method. 
Strains positive for coaggregation in the high-throughput assay were further evaluated 
using a FlowCam™ device and confocal microscopy.  Using the high-throughput assay 
there was apparent coaggregation between B. pertussis and strains of H. influenzae, P. 
aeriginosa, S. aureus, S. pyogenes, and S. pneumoniae; however visual examination 
using the FlowCam™ runs and confocal microscopy suggested induction of 
autoaggregation in B. pertussis by S. aureus and P. aeruginosa, and no interaction 
between B. pertussis and the other strains.  By inducing autoaggregation in B. pertussis, 
S. aureus and P. aeriginosa may be able to prevent B. pertussis from colonizing the host.
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3.2      Introduction 
3.2.1 Pertussis can be Carried Asymptomatically or with Minimal Symptoms  
While pertussis infection can result in severe morbidity and even mortality in 
unvaccinated infants and young children, infection in vaccinated adolescents and adults 
is generally milder and results in a prolonged cough (Conover & Sloan 2010).  Several 
studies among vaccinated and unvaccinated adults and adolescents with a cough lasting 
longer than one week, show high rates of B. pertussis in this group: from 12-32% (Cherry 
1999; Mink et al. 1992; Schmitt-Grohé et al. 1995; Wirsing von König et al. 1995; Wright 
et al. 1995; Rosenthal et al. 1995; Nennig et al. 1996). Individuals with unrecognized 
pertussis infections can serve as reservoirs for transmission in hospital settings and 
within families (Conover & Sloan 2010).  In a study of 41 infants under age 4 months and 
their household contacts, parents and siblings, nearly half of which were asymptomatic, 
were found to serve as an important source of infection (Raymond et al. 2007). 
 Only a few studies have estimated the prevalence of asymptomatic carriage.  
Among a cohort of 242 vaccinated, healthy Danish infants,  5-10% showed IgG and IgA 
antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA) by age 1 
although only a few clinical cases were recognized in the community at the time, (von 
Linstow et al. 2010).  This strongly suggests ongoing asymptomatic transmission.  
Further, among 279 children ages 5-15 years presenting to the Nuffield Department of 
Primary Care Health Sciences at Oxford University from 2010 to 2012 with a cough 
illness of two-eight weeks duration, 56 (20% ±5%) had an oral fluid anti-pertussis toxin 
IgG titre consistent with a recent pertussis infection and of those children, 39 (70%) 
were fully vaccinated (Wang et al. 2014).  
One hypothesized mechanism for B. pertussis’ ability to persist for long periods 
in the oropharynx is that B. pertussis can form biofilms (Conover & Sloan 2010; Serra et 
al. 2011; Sloan et al. 2007; Conover et al. 2011)  (Arnal et al. 2015; Conover & Sloan 
2010; Serra et al. 2011; Mishra & Parise 2005; Conover et al. 2012).  Biofilms consisting 
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solely of B. pertussis are well documented, but whether it is able to jointly form biofilms 
with other species, particularly bacteria found in the nasopharynx of human hosts, is 
unstudied.  When in a biofilm, bacteria are more resistant to antimicrobial agents such 
as detergents, antibiotics, and reactive oxygen species and are more resistant to 
clearance by the host’s immune system (Conover & Sloan 2010).  High levels of 
resistance to erythromycin and ciprofloxacin among Bordetella species in biofilms have 
been reported (Mishra & Parise 2005) and strains containing Bps, the polysaccharide 
responsible for biofilm development in Bordetella species, took an entire month to be 
fully cleared from the nose in a murine model (Conover & Sloan 2010).  This resistance 
to clearance by the host’s immune system when in biofilm form may allow B. pertussis 
to persist in the nasopharynx of asymptomatic hosts and allow them to serve as 
reservoirs of infection for unvaccinated infants (Conover & Sloan 2010; Tan et al. 2005).     
 
3.2.2 Oropharyngeal Microbiota may Influence Risk of B. pertussis Colonization 
 Household contacts of pertussis cases vary in risk of infection (including 
asymptomatic carriage) in ways not entirely explained by vaccination status or previous 
infection (Raymond et al. 2007; Cherry 1997; Ward et al. 2006).  According to the 
Centers for Disease Control and Prevention, only 9% of the children ages 6 months to 6 
years infected during 2015 had not been vaccinated. In a study following the large 2010 
pertussis outbreak in Marin County, California, no difference in attack rates were found 
between fully vaccinated and under- and un-vaccinated children demonstrating that 
vaccination status is not the primary determinant for who gets infected (Witt et al. 
2012).  
The majority of those infected are unaware that they are infected and are able 
to transmit to others (de Melker et al. 2006).  Among infants with a known source of 
infection, more than 66% of the sources of infection were immediate family members 
(Skoff et al. 2015).   In a study of IgG-PT levels (an indicator of recent pertussis infection) 
in the Netherlands, researchers estimated the incidence of recent infection in the Dutch 
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population at 6.6%, which was significantly higher than the reported incidence of 0.01% 
per year.  In addition, a study of B. pertussis seroprevalence in the Netherlands 
demonstrated that although increased vaccination has reduced morbidity due to 
pertussis among children, the infection rate in adults and adolescents has remained 
unaffected (de Greeff et al. 2010).  
 One hypothesized mediator of B. pertussis colonization is the oropharyngeal 
microbiota.  Some commensals individually or collectively may enhance and others may 
resist B. pertussis colonization.  Results from a murine model support this hypothesis. 
Among mice treated with antibiotics to remove commensals from the nasal cavity, the 
infectious dose required to obtain B. pertussis colonization was significantly reduced: to 
<100 CFU compared with the 10,000 CFU required before treatment.  However, 
reintroduction of even a single Staphylococcus or Klebsiella species to the nasal cavity 
blocked B. pertussis colonization following an inoculation of 5,000 CFU of B. pertussis, 
which is greater than ten times the dose required in antibiotic-treated mice (Weyrich et 
al. 2014).  Thus, interactions with host microbiota may mediate the ability of B. pertussis 
to form biofilms and colonize.   
 Biofilm formation often begins with coaggregation, the highly specific 
recognition and adherence of two distinct bacterial species (Rickard et al. 2003).   
Superinfection with other respiratory pathogens such as H. influenza, S. pneumoniae, 
and S. aureus is common during and after infection with B. pertussis, which hints that 
polymicrobial interactions may be an important aspect of B. pertussis infection (Sawal et 
al. 2009).  To gain insight into whether coaggregation might help explain why vaccinated 
individuals might still asymptomatically carry B. pertussis, we assessed the ability of 10 
different B. pertussis strains to coaggregate with common nasopharyngeal commensals: 
S. pneumoniae, S. aureus, and H. influenzae, S. pyogenes, P. aeriginosa, and N. 
meningitidis.  
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3.3 Methods 
3.3.1 Growth Conditions and Strains Used 
Haemophilus influenzae (strains 007.2.12, I247, G1322, I316, K29RE2.10) and 
Neisseria meningitidis, Streptococcus pyogenes, Staphylococcus aureus (strains 1263, 
25923), Pseudomonas aeriginosa, and Streptococcus pneumonia (serotypes 1, 10, 12F, 
16F, 20, 23F, 33, 34, 35B, 7F) strains were incubated aerobically with CO2 at 37°C in 
Brain Heart Infusion broth for 24 hours.  Cells were harvested from batch culture 
through centrifugation for 12.5 minutes at 3,000 X g.  B. pertussis (strains CDC_F657, 
CDC_F964, CDC_G710, CDC_H971, CDC_I220, CDC_I240, CDC_I369, WA_H174, 
WA_H930, WA_H962) was grown on Regan-Lowe agar plates at 37°C for 4 days.  
Coaggregation is known to be highly variable (Levin-Sparenberg et al. 2016), therefore, 
we also repeated experiments reducing the growth time from 24 to 18 hours for test 
strains and an increasing growth time from 4 to 5 days for B. pertussis. 
  B. pertussis cells were harvested by swabbing the surface of the agar with a 
coaggregation buffer-soaked, nylon-tipped swab and suspending the cells in 
coaggregation buffer before centrifugation for 12.5 minutes at 3,000 X g.  All cells were 
washed 3 times in coaggregation buffer (Cisar et al. 1979; Rickard et al. 2000).  After 
each centrifugation step, the supernatant was discarded and the pellet re-suspended in 
coaggregation buffer.  The washed pellets were then suspended in coaggregation buffer 
to achieve an optical density at 600 nm of 1.5 (±0.1).      
 
3.3.2 High Throughput Coaggregation and Autoaggregation Assays 
To assess coaggregation between two strains, 200 µl of each bacterial 
suspension were combined in a glass culture tube.  Autoaggregation was assessed by 
examining 400 µl of each sample and continuing with the same protocol.  The culture 
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tubes were vortexed for ten seconds and rolled gently for an additional 30 seconds 
(Rickard et al. 2000).  Samples were allowed to sit 60 minutes to let coaggregates settle 
to the bottom of the tube.  One hundred microliters of supernatant were removed from 
each sample and placed in a 96 well flat-bottom plate.  Absorbance of the supernatant 
was measured at 620 (A) using a PerkinElmer 2030 workstation (Levin-Sparenberg et al. 
2016).  All coaggregation and autoaggregation assays were conducted in triplicate.  S. 
gordonii, S. oralis, and A. oris pairs were used as positive controls on all 96-well plate 
assays. 
Results of the high-throughput screen were used to calculate mean absorbance 
and associated 95% confidence intervals for each strain pair.  Because strains were set 
to the same optical density (1.5) before combining, an expected value for the combined 
pair was calculated based on the average experimental OD of the two components.  The 
mean absorbance, 95% confidence interval, minimum and maximum for each pair was 
then compared with the expected value for the pair.  Coaggregation was suspected 
when the upper limit for the 95% confidence interval was below the expected value and 
was considered when the mean OD was below the expected value (Levin-Sparenberg et 
al. 2016). 
 
Example Calculation of Expected 
Value: 
 
CONTENTS N 
Mean over 3 
trials 
ODBUG
1 
ODBUG
2 EXPECTED VALUE 
CDC_F657+CDC_F657 3 0.31 0.31 0.31   
S. aureus 1263+S. aureus 1263 3 0.39 0.39 0.39   
CDC_F657+S. aureus 1263 3 0.23 0.31 0.39 
(0.31+0.39)/2= 
0.35 
 
The empirically determined mean OD over the three replicates of CDC_F657+S. aureus 
1263 was 0.23 (95% CI:   0.18, 0.28) which is less the expected value for the pair based 
on the average of the empirically determined OD for each of the components. As the 
value is less than the expected value this suggests that CDC_F657+S. aureus 1263 
coaggregate.   
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3.3.3 FlowCam™ Imaging and Quantification of Coaggregation 
Following an initial screen of our strain pairs using the high-throughput method, 
we identified pairs where the mean observed OD for the pair was less than the expected 
value.  These pairs were further evaluated for coaggregation using FlowCam™ 
technology (Fluid Imaging Technologies, ME, USA), which uses flow cytometry to 
measure particle size over time (Levin-Sparenberg et al. 2016).  P. aeriginosa, H. 
influenzae 007.2.12 and 1247, S. aureus 1263, S. pneumoniae serotype 10, and N. 
meningitidis were harvested from batch cultures and washed as described above.  The 
washed pellets were suspended in coaggregation buffer to achieve an optical density of 
1.0 (±0.1) at 600 nm.  Prior to loading the cells into the FlowCam device, cell 
suspensions were further diluted 10X in coaggregation buffer to prevent clogging of the 
flow cell.  We experimented with both 5X and 10X dilution and found a 5X dilution 
factor resulted in repeated clogging of the flow cell (Levin-Sparenberg et al. 2016; 
Segaloff et al. 2014).  The first species was added to the device and was pumped 
through until it reached the flow cell.  Data collection began once the Olympus UPlanFL 
N 10X/0.30 objective was successfully focused on the flowing particles.  The second 
species was added to the vessel containing the first species and gently mixed one 
minute after initiation of data collection.  FlowCam was run at a flow rate of 0.3 ml/min 
with images acquired at a rate of 10 frames per second, until the entire sample ran 
through the machine (45-55 min).  Flash duration was set to 8 µSec.   Particle size was 
measured using area based diameter (ABD) and a particle filter of 0.5 to 10,000 μM.  
Visual spreadsheet software was used for data collection. 
 
3.3.4 Confocal Microscopy 
As an additional visual test of autoaggregation and coaggregation between strains, 
300 μl of each bacterial suspension in coaggregation buffer were stained with either 
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syto-9 (green: Excitation:  488, Emission: 503) or syto-61 (red: Excitation: 561, Emission: 
645) nucleic acid stains (Invitrogen, Carlsbad, CA, USA). Each bacterial suspension was 
incubated for 30 minutes at room temperature to allow staining of the cells.  Cells were 
washed three times with 1X PBS (phosphate buffer solution) and collected by 
centrifugation, as described above. Each bacterial strain was re-suspended in 
coaggregation buffer and combined for coaggregation.  Autoaggregation studies consist 
of only one color stained cells.   Twenty microliters of each sample were added to the 
slide and viewed under the microscope.  The entire droplet was scanned and a 
minimum of three representative fields of view were captured for each pair and for 
each strain alone using Leica confocal laser scanning microscopy (CLSM, SPE, Leica, IL, 
USA) with a HCX PL APO 40X/0.85 CORR CS objective.  Staining and microscopy were 
repeated twice to ensure consistency of results.  Once the microscopy images were 
taken, the image files were rendered using Imaris (Bitplane, Zurich, Switzerland) 
computer imaging software.   
3.4 Results and Discussion 
3.4.1 Autoaggregation not detected by high-throughput screen 
 None of the B. pertussis or commensal strains showed autoaggregation on the 
high-throughput screen. However, when examined using confocal microscopy, 
autoaggregation was apparent in N. meningitidis.  Autoaggregation in N. meningitidis is 
mediated by PilX, a type IV pilus-associated pilin-like protein (Lappann et al. 2006). 
3.4.2 High-throughput screen identifies potentially coaggregating pairs 
 Using the high-throughput screening method, we examined 133 unique pairs of 
bacteria for coaggregation and autoaggregation.  Each pair was screened at least three 
times, and as many as 33 times, with an average of six screens per pair.  Based on an 
experimentally determined OD value that was significantly less than the calculated 
expected value for the pair, H. influenzae (strains 007.2.12, I247, I316, K29RE2.10), P. 
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aeriginosa, S. aureus (strains 1263 and 25923), S. pyogenes, and S. pneumoniae 
(serotypes 1, 10, 16F, 20, 23F, 33, 34, 35B) were suspected as coaggregating with at 
least one of the ten B. pertussis strains tested (green circles, Figure 3.1).   In addition S. 
pneumoniae 7F and 12F, N. meningitidis, H. influenzae G1322 also potentially 
coaggregated with at least one strain of pertussis based on OD values less than the 
expected values, although not significantly so (yellow circles, Figure 3.1).   
Results were quite variable.   An organism would coaggregate with one strain of 
B. pertussis, but not others, or coaggregated with a particular strain one day and not the 
next.  This variation is strikingly evident when examining the results of the control strain 
pairings, A. oris+ S. oralis, S. oralis + S. gordonii, and A. oris + S. gordonii (Figure 3.1).  
Although these strains are known to strongly coaggregate, results varied by day from 
coaggregating significantly to not at all.  Many factors could contribute to between day 
variations:  bacteria are harvested from separately grown batch cultures, which may 
differ slightly in length of growth time, exact nutrient content and pH of media, pH of 
buffers used for washing and re-suspension, number of times a strain has been 
passaged before current growth, and natural biological variation in amount of 
autoaggregation or coaggregation within a given species or species pair.   
 Based on the results of the high-throughput screen, summarized in Figure 3.1, 
and visual assessment of test crosses, we selected one B. pertussis strain, CDC-F567, and 
7 test strains (H. influenza I247, N. meningitidis, P. aeriginosa, S. aureus 1263, and S. 
pneumoniae serotypes 10 and 16F, and S. pyogenes) for further analysis using 
FlowCam™ and confocal microscopy. 
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Table 3.1 Summary of high-throughput coaggregation screen results.  Green circles represent 
OD values significantly less than expected value.  Yellow dots represent OD values less than 
expected values.  Red dots represent no difference between OD and expected value or OD 
higher than expected value. 
 
A. oris CDC_F657 CDC_F964 CDC_G710 CDC_H971 CDC_I220 CDC_I240 CDC_I369 H. flu 007.2.12 H. flu I247 H. flu G1322
A. oris
CDC_F657
CDC_F964
CDC_G710
CDC_H971
CDC_I220
CDC_I240
CDC_I369
WA_H174
WA_H930
WA_H962
H. flu 007.2.12
H. flu G1322
H. flu I316
H. flu K29RE2.10
N. meningitidis
P. aeriginosa
S. aureus 1263
S. aureus 25923
S. gordonii
S. oralis
S. pyogenes
SP1
SP10
SP12F
SP16F
SP17F
SP20
SP23F
SP33
SP34
SP35B
SP7F
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H. flu I316 H. flu K29RE2.10 N. meningitidis P. aeriginosa S. aureus 1263 S. aureus 25923 S. gordonii S. oralis S. pyogenes SP1 (vaccine)
SP10 (10 is in 
23valent 
A. oris
CDC_F657
CDC_F964
CDC_G710
CDC_H971
CDC_I220
CDC_I240
CDC_I369
WA_H174
WA_H930
WA_H962
H. flu 007.2.12
H. flu G1322
H. flu I316
H. flu K29RE2.10
N. meningitidis
P. aeriginosa
S. aureus 1263
S. aureus 25923
S. gordonii
S. oralis
S. pyogenes
SP1
SP10
SP12F
SP16F
SP17F
SP20
SP23F
SP33
SP34
SP35B
SP7F
0.33 0.56 0.11 0.5 0.38 0.13
0.5 0.5
0.5 0.5
0.64 0.18 0.18
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3.4.3 FlowCam results inconclusive 
The FlowCam™ device allows individual particles to be photographed and the 
particle characteristics measured.  As a coaggregation assay it can be used to measure 
the change in particle size over time (Levin-Sparenberg et al. 2016).  None of the B. 
pertussis pairings appeared to strongly coaggregate in the FlowCam™ device.  The large 
SP12F (in 23 
valent)
SP16F (not 
vaccine) SP20 (23 valent) SP23F (vaccine) SP33 (23 valent)
SP34 (not 
vaccine)
SP35B (not 
vaccine) SP7F (vaccine) WA_H174 WA_H930 WA_H962
A. oris
CDC_F657
CDC_F964
CDC_G710
CDC_H971
CDC_I220
CDC_I240
CDC_I369
WA_H174
WA_H930
WA_H962
H. flu 007.2.12
H. flu G1322
H. flu I316
H. flu K29RE2.10
N. meningitidis
P. aeriginosa
S. aureus 1263
S. aureus 25923
S. gordonii
S. oralis
S. pyogenes
SP1
SP10
SP12F
SP16F
SP17F
SP20
SP23F
SP33
SP34
SP35B
SP7F
0.5 0.5 0.5 0.5
0.5 0.5
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confidence intervals in the B. pertussis + H. influenzae H1247 pairing are reflective of the 
large variability of particle sizes through the flow cell at a given time point (Figure 3.2, 
Panel A).  This indicates a combination of single bacterial cells and cell aggregates.  Any 
cell aggregates formed are not large enough to rapidly drop out of the suspension 
resulting in no significant time component.  Coaggregation in this pair was not strong 
enough to detect with a visual assay.  Another study that examined coaggregation 
between H. influenzae and 30 other species also detected no visual coaggregation with 
H. influenzae (Stevens et al. 2015).  In the B. pertussis F657+ P. aeriginosa pairing, there 
were significant increases in particle area starting around minute 53 (Figure 3.2, Panel 
B).  In the combination of B. pertussis F657+ N. meningitidis a slight, although 
statistically significant, increase in particle area began at minute 14 (Figure 3.2, Panel C).  
In combinations of B. pertussis F657 with S. pneumonia 16F and S. pyogenes, a 
significant increase in particle size occurred immediately followed by a sharp decrease in 
particle size (Figure 3.2, Panel D and E).  This could potentially occur if larger particles 
immediately fall out of suspension and are captured in the flow cell first, leaving only 
single cells remaining. 
As with the visual assay and high-throughput screening method, there was a lot 
of run to run variation.  Runs with stronger aggregation were more likely to be thrown 
out due to the larger particle sizes clogging the flow cell and interrupting the run.  While 
the second bacterial species was added one minute after initiation of data collection to 
create a separation between B. pertussis alone and when combined with another 
species, increases in particle size could be due to either coaggregation or either species 
inducing autoaggregation in the other.  Due to inconsistencies between runs and issues 
with clogged flow cells, we were unable to reach any general conclusions as to the 
ability of B. pertussis F657 to coaggregate with these other species.      
In an attempt to clarify our conclusions and obtain more consistent results we 
tested the effect of changing growth times for the bacteria by reducing growth time 
from 24 hours to 18 hours for the test strains, and increased growth time from four to 
five days for B. pertussis.  We found no noticeable effect on our results by manipulating 
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growth times.  We also experimented with changing the dilution factor from 1:10 to 1:5 
in hopes of inducing coaggregation.  This resulted in blocked flow cells which may have 
been a result of increased coaggregation, but also resulted in unusable data.  We also 
assessed the effects of switching from coaggregation buffer to PCR-grade water and 
from the use of Schaedler’s broth to BHI broth for growth of test strains, but found no 
noticeable difference in results. 
 
 
Figure 3.1  Average particle area per minute with associated 95% confidence intervals as 
measured with FlowCam device. 
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3.4.4 Confocal microscopy  
To further understand the interactions between B. pertussis and other 
nasopharyngeal commensals, we stained our strains using Syto-9 (green) or Syto-61 
(red) nucleic acid stains before crossing them for coaggregation, and then visualized 
using a confocal microscope.  Each strain was also imaged on its own to rule out any 
autoaggregation.  N. meningitidis appears to be the only strain that auto-aggregated 
(Figure 3.3, panel C).  If coaggregation were present, we would expect to see large 
clusters of overlapping green and red cells, which was not apparent in any of our 
crosses.  Mixing B. pertussis with S. aureus appeared to result in auto-aggregation of S. 
aureus (Figure 3.3, panel A).  Mixing B. pertussis with H. influenzae HI247 appeared to 
result in slight auto-aggregation in H. influenzae (Figure 3.3, panel B).  Crossing B. 
pertussis with N. meningitidis appeared to enhance autoaggregation of N. meningitidis 
(Figure 3.3, panel C).   Combining B. pertussis with P. aeriginosa induced 
autoaggregation in both strains (Figure 3.3, panel D).  The combination of B. pertussis 
with S. pneumoniae serotype 10 appeared to induce slight autoaggregation in S. 
pneumoniae (Figure 3.3, panel E.) 
Based on our findings that the presence of B. pertussis may result in 
autoaggregation of one or both species, we attempted to determine if B. pertussis was 
excreting a molecule that induces autoaggregation.  For this experiment we grew B. 
pertussis and suspended the cells in coaggregation buffer as described in the methods.  
The cells were allowed to remain in the buffer for an hour and then were filtered out.  
The buffer was saved and added to the other test strain cells in the FlowCam™ device 
rather than adding the B. pertussis cells themselves.  This method did not induce auto-
aggregation in the test strains.   
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F657 
 
Figure 3.2. FlowCam Visualization of selected bacterial pairings using confocal microscopy.  
Confocal microscopy images are represented in the x-y plane. Nucleic acid stains syto-9 
(green) and syto-61 (red) was used to detect autoaggregation and coaggregation of bacterial 
strains. Bars represent 10 μM. 
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3.4.5 Conclusion 
We did not identify autoaggregation in any of the B. pertussis or commensals 
strains with the use of the high throughput screen.  Further screening with confocal 
microscopy identified autoaggregation in N. meningitidis.   
While there appears to be an interaction between B. pertussis and selected 
commensals, we conclude that it is not due to coaggregation between B. pertussis and 
the nasopharyngeal test strains.  Based on our confocal microscopy results, the co-
occurrence of B. pertussis with one of the test strains may induce auto-aggregation in 
one or both strains, although we were unable to confirm this.  
Superinfection with other respiratory pathogens such as H. influenzae, S. 
pneumoniae, and S. aureus is common during and after infection with B. pertussis, 
which hints that polymicrobial interactions may be an important aspect of B. pertussis 
infection (Sawal et al. 2009).  The specific mechanism of interaction between B. 
pertussis and the resident bacteria is unknown. Bordetella species contain many 
mechanisms for interbacterial competition that could be at play, including a type IV 
secretion system for secretion of pertussis toxin, bacteriophages, and potentially 
contact-dependent growth inhibition (Weyrich et al. 2014). Coaggregation is common 
among oral bacterial and would be a reasonable mechanism if certain resident 
microorganisms are necessary for B. pertussis to attach.  However if the findings from 
the murine model hold in humans, that the presence of nasopharyngeal microbiota 
prevents efficient colonization by B. pertussis, antagonistic coaggregation interactions 
could be responsible, or as we saw some evidence of in our results, induced 
autoaggregation on one or both species in the presence of B. pertussis. 
To the authors’ knowledge, this is the first study of coaggregation in B. pertussis.  
While we did not find evidence to support coaggregation between B. pertussis and the 
organisms studied, we did find some indication that autoaggregation of one or both 
species is induced in the presence of B. pertussis.  Further study is needed to better 
understand the role of microbiota in aiding or abating B. pertussis infection in humans.  
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A better understanding of how the microbiota is involved could result in better 
treatment and prevention methods for B. pertussis infection.   
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 Epidemiologic Evidence for Co-colonization of Selected Commensals and Chapter 4.
Asymptomatic B. pertussis Carriage  
 
4.1 Abstract 
We hypothesized that the presence of commensals in the oropharynx might 
enhance or decrease Bordetella pertussis colonization.  To test this hypothesis, we 
planned to screen an archival collection of nasopharyngeal swab specimens collected as 
part of a cross-sectional study of nasopharyngeal S. pneumonia carriage in Phu Vinh 
hamlet of Vinh Thanh commune, Nha Trang district, Vietnam during October, 2006, for 
asymptomatic B. pertussis carriage and that of selected commensals.  Since the 
Expanded Programme on Immunization was introduced in Vietnam in 1981, vaccination 
rates with the whole cell vaccine increased and remain high. Four samples were positive 
for B. pertussis, but the prevalence of S. aureus was significantly less than expected 
based on previous studies suggesting that during handling or storage that the quality of 
the samples was compromised.  Thus it is likely that the estimated prevalence of B. 
pertussis is also in error. Due to issues with sample quality, the study ended early with 
inconclusive results.   
4.2 Introduction 
The United States has seen a dramatic increase in the number of reported B. 
pertussis cases since the introduction of the acellular vaccine in the 1990s (Centers for 
Disease Control and Prevention 2016).  Some studies have proposed asymptomatic 
transmission from individuals vaccinated with acellular vaccines as a potential 
mechanism for the increase in number of cases although little is known about the actual 
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prevalence of asymptomatic carriage (Althouse & Scarpino 2015; Zhang et al. 2014; 
Cortese et al. 2007; de Melker et al. 2006).  Another important aspect of this resurgence 
is that a large proportion of these cases have occurred in fully vaccinated individuals 
making it clear that factors outside of vaccination status also influence who becomes 
infected (Centers for Disease Control and Prevention 2016).  We hypothesized that 
bacterial commensals in the nasopharynx of potential hosts might enhance or decrease 
the risk of B. pertussis colonization.  We screen archival nasopharyngeal swabs collected 
from healthy individuals to estimate the prevalence of asymptomatic carriage of B. 
pertussis and co-occurrence with select commensals. 
 
4.2.1 Asymptomatic Carriage as a Mechanism for Resurgence in Reported Cases 
Warfel et al. propose that asymptomatic infection and subsequent transmission 
by individuals vaccinated with the acellular vaccine could, in part, explain the increase in 
observed B. pertussis incidence (Warfel et al. 2014).  Using a baboon model for B. 
pertussis infection, Warfel et al. and found that while vaccination with acellular 
pertussis (ap) protected against severe symptoms, it did not protect against colonization 
(Warfel et al. 2014).  Moreover, vaccinated animals did not clear the infection any faster 
than naïve animals and could readily transmit B. pertussis to their unvaccinated contacts 
(Warfel et al. 2014).  By comparison, more rapid clearance was induced by the whole 
cell vaccine and animals that were previously infected were not colonized upon 
secondary infection (Warfel et al. 2014).  In addition, re-analyses of aP efficacy studies 
using more sensitive serologic diagnostic criteria found that while pertussis toxoid alone 
protects against typical laboratory-confirmed pertussis infection, it does not protect 
against colonization or infection (Storsaeter et al. 1990).  To provide further evidence 
for the importance of asymptomatic transmission, Althouse and Scarpino used wavelet 
analysis of B. pertussis incidence and phylodynamic analysis of clinical isolates.  Their 
analysis of the sequences showed more genetic diversity in the bacterial population 
than could be explained by the observed number of infections without the possibility of 
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asymptomatic carriage and that the time of changes in age-specific attach rates were 
consistent with asymptomatic transmission (Althouse & Scarpino 2015). 
While these studies point out the potential importance of asymptomatic carriage 
in transmission dynamics, only a limited number of studies aimed at estimating the 
prevalence of asymptomatic carriage have been conducted.  Using IgG and IgA 
antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA), von Linstow et 
al. found that 5-10% of a cohort of vaccinated, healthy children had evidence of B. 
pertussis infection during their first year of life despite few clinical cases recognized in 
the community at the time (von Linstow et al. 2010).  In a sample of nasopharyngeal 
swabs from asymptomatic Chinese school children ages 7 to 15, 2/629 (0.3%) were both 
culture-positive and PCR-positive and 30/269 (4.8%) were PCR-positive (Zhang et al. 
2014). Although the prevalence was low, positive samples were found in all four 
counties studied (Zhang et al. 2014).   
To understand if the prevalence of asymptomatic carriage has increased with the 
introduction of acellular vaccines, it is important to have estimates of the prevalence in 
countries where vaccination rates with the whole cell vaccine are high as a comparison.  
The Expanded Programme on Immunization (EPI) was introduced in Vietnam in 1981 (Jit 
et al. 2015).  By 2009, 96% of children under age one had received three or more doses 
of whole cell pertussis vaccine (Jit et al. 2015; Anh et al. 2015).  We screened archival 
nasopharyngeal swabs collected from healthy individuals in Vietnam to estimate the 
prevalence of asymptomatic carriage in this highly vaccinated population.   
 
4.2.2 Nasopharyngeal Commensals as a Determinant of B. pertussis Infection 
Superinfection with other respiratory commensals such as H. influenza, S. 
pneumoniae, and S. aureus is common during and after infection with B. pertussis 
hinting that polymicrobial interactions may be an important aspect of B. pertussis 
infection (Sawal et al. 2009).  As further evidence of the importance of nasopharyngeal 
commensals as a determinant of pertussis infection, Weyrich et al. demonstrated that 
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treating mice with antibiotics to remove resident microorganisms from the murine nasal 
cavity greatly enhanced B. pertussis colonization.  For B. pertussis to colonize in 
presence of even a single naval cavity bacterial species required ten times the dose 
needed in antibiotic treated mice (Weyrich et al. 2014).  This led us to hypothesize that 
specific interactions between B. pertussis and nasopharyngeal commensals might 
enhance or decrease B. pertussis colonization and help explain why vaccinated 
individuals might still asymptomatically carry B. pertussis.  
 In a preliminary screen for coaggregation (specific recognition and adherence 
between distinct bacterial species) between 10 different B. pertussis strains with 
common nasopharyngeal commensals: S. pneumoniae, S. aureus, H. influenzae, S. 
pyogenes, P. aeriginosa, and N. meningitidis, we obtained results consistent with 
coaggregation between B. pertussis and H. influenzae, P. aeriginosa, S. aureus, S. 
pyogenes, and S. pneumoniae with the use of our high-throughput, quantitative 
screening method (Levin-Sparenberg 2016).  Based on further analysis using FlowCam™ 
and confocal microscopy, we did not find evidence to support coaggregation between B. 
pertussis and the organisms studied, but did find some indication that autoaggregation 
of one or both species is induced in the presence of B. pertussis (Levin-Sparenberg 
2016).  Autoaggregation was particularly apparent between B. pertussis and P. 
aeriginosa and S. aureus  species (Levin-Sparenberg 2016).  The purpose of this study 
was to determine if there was evidence that these in vitro interactions between B. 
pertussis and selected commensals also occurred in vivo. 
 
4.2.3 Study Objectives 
 This study had two objectives:  1) to assess the prevalence of asymptomatic B. 
pertussis carriage in a population with high whole cell vaccination rates, and 2) to 
determine if specific nasopharyngeal commensals co-occur with B. pertussis in the 
nasopharynx of healthy individuals in an effort to better understand why some 
individuals get colonized while others do not.  For this study, we screened archival 
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nasopharyngeal swabs from a sample of 519 healthy individuals collected from Phu Vinh 
hamlet of Vinh Thanh commune, Nha Trang district, Vietnam during October, 2006, to 
estimate the prevalence of asymptomatic carriage of B. pertussis in a population with 
high whole cell vaccination rates.  We additionally screened for the prevalence of H. 
influenzae, S. pneumoniae, P. aeriginosa, and S. aureus to determine if they co-occur 
with B. pertussis. 
4.3 Methods 
4.3.1 Archival Collection 
The archival nasopharyngeal swabs were collected as part of a cross-sectional 
study of nasopharyngeal (NP) S. pneumonia carriage in Phu Vinh hamlet of Vinh Thanh 
commune, Nha Trang district, Vietnam during October, 2006 (Talerico et al. 2009).  
Households in Phu Vinh with at least one child five years or younger and households 
with adults only (≥ 18 years) were randomly selected from a detailed census list 
compiled by the Khanh Hoa Provincial Health Service and invited to participate.  
Households were recruited by trained interviewers until 75 households with children (≤ 
5 years) and 40 households comprised of only adults were enrolled.  All current 
household members were invited to participate in an interview survey and NP swab 
procedure. Out of the 146 households that were approached, 115 participated (79%).  
Out of the 96 households with young children that were approached, 75 (78%) agreed 
to participate.  Forty households containing only adults, out of the fifty households 
approached, agreed to participate (80%).  The reason most commonly cited for refusal 
was that all household members were not available to participate due to extensive 
travel required for employment (Talerico et al. 2009).  
NP swab procedures took place at the Vinh Thanh Commune Health Center and 
were obtained from all participants by trained physicians, in accordance with World 
Health Organization recommendations (O’Brien et al. 2003).  Three households, which 
previously contained only adults, switched to the households with one child ≤ 5 years 
group in the analysis due to the birth of a child between recruitment and survey 
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administration.  Therefore, 78 households contained at least one child ≤ 5 years and 37 
households contained only adults (≥ 18 years) (Talerico et al. 2009). 
Specimens were collected using calcium alginate-tipped wire swabs (Calgiswab® 
Type 1, Puritan Medical Products Company LLC, Guilford, ME).  Swabs were passed 
through the anterior nares to the back of the nasopharynx, held in place for two 
seconds, and rotated 180° before removal.  After collection, swab specimens were 
placed in STGG transport media and held at 4°C for no more than four hours at the 
Commune Health Center before being transported to the local hospital where they were 
stored at -20°C for one week (Talerico et al. 2009).  NP swabs were ultimately shipped 
on dry ice to the University of Michigan and stored at -80°C (O’Brien et al. 2003). 
Informed consent for the original study was obtained from all adults (≥ 18 years) 
and parents of children prior to participation (Talerico et al. 2009). In addition, oral 
assent was obtained from participants 6-17 years old prior to the NP swab procedure 
(Talerico et al. 2009).  All study procedures were approved by the Health Sciences 
Institutional Review Board (IRB) at the University of Michigan (HUM00006257), the IRB 
of the National Institute of Hygiene and Epidemiology in Hanoi, Vietnam, and the IRB of 
the International Vaccine Institute in Seoul, Korea (2006-009).  Use of the archival swab 
samples for this project received a determination of “Not Regulated” Status by the 
University of Michigan (HUM00115197). 
 
4.3.2 Laboratory Methods 
DNA was extracted using a QIAGEN (Venlo, Netherlands) DNeasy Blood & Tissue 
kit.  One hundred microliters of each sample was first incubated at 37°C with an 80 μL 
enzyme cocktail comprised of Promega cell lysis solution (Madison, WI, USA), lysozyme, 
mutanolysin, RNase A, and lysostaphin (Sigma Aldrich) in 22.5:4.5:1.125: 1.125:1 parts, 
respectively for 30 minutes. After extraction, DNA quantity and quality was measured 
using a Nanodrop 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA) 
and stored at −80°C.  
 60 
 
4.3.3 Identification of B. pertussis and commensals 
To identify B. pertussis, we first screened for IS481, an insertion sequence found in 
multiple copies in B. pertussis, and then screened positive samples with primers specific 
to pertussis toxin subunit S1 (ptxS1), B. parapertussis IS1001 (pIS1001), and B. holmesii 
IS1001-like (hIS1001) targets (Table 1) (Tatti et al. 2011).  This combination of primers 
can be used to distinguish B. pertussis from other Bordetella species (Table 2).  Samples 
positive for B. pertussis were also screened for P. aeriginosa using primers for gyrB and 
S. aureus with primers specific to nucA (Table 1) (O G Brakstad 1992; Lee et al. 2011). A 
random sample of the remaining isolates (n=213) was screened for P. aeriginosa and S. 
aureus to determine the background rate of these organisms in the collection.  We used 
a 50 µl reaction mixture for all reactions composed of 25 µl GoTaq Green Master Mix 2X, 
1 µl forward primer, 1 µl reverse primer, 15 µl sample DNA, and 8 µl PCR-Grade H20.  
The following program was used to amplify IS481:  1 = 95°C for 2 min, 2 = 95°C for 30 
sec, 3 = 65°C for 30 sec, 4 = 72°C for 20 sex, 5 = GOTO 2 29 times, 6 = 4°C forever.   Step 
3 was switched to 57°C for ptxS1 and to 60°C for all other primer sets.  PCR products 
were visualized on 2% agarose gels.  All PCR reactions were conducted in duplicate. 
To identify samples positive for H. influenzae, NP swabs from all participants were 
plated on chocolate bacitracin agar and incubated overnight at 37°C with 5% CO2.  Thirty 
colonies were picked and patched on chocolate agar plates without bacitracin.  A 
porphyrin test was performed on each patch.  Positive results were considered para-
influenza.  Samples were also plated on Brain Heart Infusion (BHI) agar with hemin only 
(X), NADH only (V) and hemin and NADH (X and V).  Samples positive for H. influenzae 
will only grow on BHI with hemin and NADH.  Stocks were prepared from the BHI (X and 
V) plates.  PCR was performed on these samples using primers specific for lgA and LgtC.  
Samples were considered positive for H. influenzae if they were porphyrin negative, BHI 
(X and V) positive and IgA and LgtC positive (Patel 2009).   
To identify samples positive for S. pneumoniae, NP samples from all participants 
were inoculated on trypticase soy agar with 5% sheep blood (TSA II) containing 
gentamicin (2.5 mg/L) and separately on non-selective media (TSA II).  Plates were 
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incubated at 37°C in 5% CO2 overnight (O/N).  Presumptive identification of S. 
pneumoniae was based on colony morphology and α-hemolysis on blood agar (O’Brien 
et al. 2003). Confirmatory identification was based on optochin sensitivity (zone ≥14 mm 
with 6mm P discs after O/N incubation at 37°C in 5% CO2), solubility in 10% 
deoxycholate using the plate method, and Gram stain ((O’Brien et al. 2003; Talerico et 
al. 2009).  Capsular typing was performed as described elsewhere and also served as a 
confirmatory measure for presence of S. pneumoniae (Talerico et al. 2009). 
 
Table 4.1.  Sequences and amplicon lengths of primers used in PCR assays 
Primer Sequence (5’ -> 3’) Amplicon length (bp) Source 
IS481 
GAT TCA ATA GGT TGT ATG CAT GGT T 
390 (Fry et al. 2009) 
TTC AGG CAC ACA AAC TTG ATG GGC G 
ptxS1 
CGCCAGCTCGTACTTC 
55 (Tatti et al. 2011) 
GATACGGCCGGCATT 
pis1001 
TCGAACGCGTGGAATGG 
65 (Tatti et al. 2011) 
GGCCGTTGGCTTCAAATAGA 
his1001 
GGCGACAGCGAGACAGAATC 
67 (Tatti et al. 2011) 
GCCGCCTTGGCTCACTT 
gyrB 
GGCGTGGGTGTGGAAGTC 
190 (Lee et al. 2011) 
TGGTGGCGATCTTGAACTTCTT 
nucA 
GCGATTGATGGTGATACGGTI 
270 (O G Brakstad 1992) 
AGCCAAGCCTTGACGAACTAAAGC 
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Table 4.2.  Algorithm for single target PCR assays 
 IS481 ptxS1 pIS1001 hIS1001 
B. pertussis + + - - 
B. parapertussis a  + +  
B. holmseii +   + 
B. pertussis + B. parapertussis a + + +  
B. pertussis + B. holmseii + +  + 
a A specimen positive for pIS1001 most likely contains B. parapertussis, but B. 
bronchiseptica cannot be ruled out.  (Tatti et al. 2011; European Centre for Disease 
Prevention and Control 2012) 
 
4.4 Results 
Out of the 519 samples, four were positive for IS481 (ID numbers 143014008, 
143019605, 143019603, 143019604).  The same four samples were also positive for 
ptxS1 and negative for pIS1001 and hIS1001 and as such were identified as positive for 
Bordetella pertussis.  These four samples were negative for P. aeriginosa and S. aureus 
based on PCR results and were negative for S. pneumoniae and H. influenzae based on 
historical data collected from the samples using the methods described above (Talerico 
et al. 2009).   
Fifty-six of the 519 samples (11%) were positive for S. pneumoniae (Talerico et al. 
2009).  Thirty-nine samples were positive for H. influenzae (8%) (Patel 2009).  H. 
influenzae was found only in samples that also contained S. pneumoniae. 
To determine the number of samples we needed to screen to estimate the 
background carriage rates for S. aureus and P. aeriginosa, we used estimates of the S. 
aureaus carriage rate, which required the larger sample size, from the literature in a 
power calculation.  In a meta-analysis conducted by Kluytmans et al. consisting of 18 
cross-sectional studies of oropharyngeal S. aureus carriage in the general population 
representing 13,873 people, the mean carriage rate was estimated at 37.2% and ranged 
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from 19.0% to 55.1% (Kluytmans et al. 1997).  In a study of 497 healthy children ages 6-
17, 53.1% were identified as S. aureus carriers (Esposito et al. 2014).  Based on our 
power calculation, we needed to screen 200 samples. Of the first 88 samples screened, 
none were positive for S. aureus.  As this was highly-inconsistent with the literature, no 
further samples were screened.  
4.5 Discussion 
This study aimed to determine the prevalence of B. pertussis carriage in a sample 
of healthy Vietnam residents and to determine its co-occurrence with other common 
nasopharyngeal commensals.  As we only found four samples that were positive for B. 
pertussis, less than we expected based on the sparse literature available, we were 
severely underpowered to make any statistically valid estimates of co-occurrence 
between B. pertussis and any of the commensals.  Ideally, in addressing this question, 
one would sample based on B. pertussis case status to have more power to detect 
commensals correlated with infection status.  However, we were also interested in 
determining the prevalence of asymptomatic B. pertussis carriage so this sample 
addressed our needs for that question.  Consistent with the literature, we did find that 
none of the commensals we screened for (H. influenzae, S. pneumoniae, S. aureus, P. 
aeriginosa) were present in the samples that were positive for B. pertussis (Weyrich et 
al. 2014). 
Expected background rates for the commensals were taken from the literature to 
estimate the number of samples in our study that we would expect to see positive for 
each of the species.  This was used to calculate the number of specimens from our 
sample that should be screened to calculate background rates for each of the samples in 
our collection.  Based on the literature, we expected roughly 40% of our specimens to 
be positive for S. aureus (Kluytmans et al. 1997; Ebruke et al. 2016; Sivaraman et al. 
2009; Esposito et al. 2014).  After screening the first 88 specimens of the 213 specimen 
sample we generated to calculate background rates for each of the commensals, none 
were found positive for S. aureus.  This is highly inconsistent with the literature.  As such 
 64 
 
the historical specimens used were deemed unreliable for additional study, and the 
study ended.   
It is likely that the true number of positive B. pertussis samples in the collection is 
higher than we were able to detect.  The DNA was tested for viability at the beginning of 
the experiment by taking a random sample of specimens deemed positive for S. 
pneumoniae by the researcher who originally collected the samples, and then screening 
for S. pneumoniae using PCR for the lytA gene.  Out of the ten presumptive positive 
samples that we screened, nine resulted in positive determination giving us the false 
impression that the rest of the samples would be viable.  Questionable quality is an 
inherent risk of archival samples, and further screening of the samples before use in the 
study could have prevented this outcome. 
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 Effects of Widespread Vaccination on the Bordetella pertussis Genome Chapter 5.
 
5.1 Abstract 
Following the implementation of widespread vaccination in the 1940s in the 
United States, the number of reported pertussis cases in North America decreased by 
over 90%; however, since introduction of the acellular vaccine in the 1990s, the annual 
number of reported pertussis cases in the United States has increased 18-fold. The 
reason for this increase is not entirely clear; one hypothesized mechanism is antigenic 
divergence of circulating strains in response to selective pressures from vaccines.  We 
conducted whole genome sequencing on a collection of 100 isolates dating from 1935 
(pre-vaccine era) to 2013 (current vaccine components and schedule).  Isolates were 
randomly selected from 8 different vaccine-related time periods: 1935-1945 Pre-vaccine 
era, 1946-1969 Early whole cell vaccine era, 1970-1990 Late whole cell vaccine era, 
1991-1996 Combination of whole cell vaccine and acellular vaccine for 4th and 5th 
doses, 1997-1999 Early acellular vaccine era, 2000-2002 Middle acellular vaccine era, 
2003-2005 Late acellular vaccine era, and 2006-2013 Tdap booster era.  Across all 
samples, this collection varied from the Tohama 1 reference genome by 3,018 single 
nucleotide polymorphisms (SNPs).  The phylogeny revealed 2 main clades and a distinct 
separation between the pre-vaccine era isolates and the rest of the collection 
(p<0.0001).  These results support a significant effect of vaccination on extinction of 
strains resulting in a replacement of populations. 
5.2 Introduction 
Pertussis (Whooping Cough) is a highly infectious upper respiratory infection 
caused by the bacteria Bordetella pertussis, characterized by violent and uncontrollable 
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coughing (Halperin SA 2012).  Although individuals of all ages can be infected, 
complications in infants are more common and can result in permanent disability or 
death (Halperin SA 2012).  Widespread vaccination has decreased the number of 
reported pertussis cases in North America by over 90% since vaccination began in the 
1940s (Halperin SA 2012); however, the past few years have seen a resurgence of 
pertussis cases in the United States that coincides with the introduction of the acellular 
vaccine (Centers for Disease Control and Prevention 2016).  In 2012, 41,880 pertussis 
cases were reported, which is the highest number of reported cases in the United States 
since 1955 (Centers for Disease Control and Prevention 2016).  Although a resurgence of 
pertussis has been reported in other highly vaccinated countries including Norway, 
Australia, and the Netherlands, there is considerable geographic heterogeneity in 
resurgence (Jackson & Rohani 2013).  Spain and some other highly vaccinated countries 
have seen a significant decrease in cases, and Argentina has seen no significant change 
in pertussis incidence (Jackson & Rohani 2013).  
The reason for the increase in number of pertussis cases reported in the US is 
not entirely clear.  Some of the current hypotheses include:  waning immunity over time 
following vaccination or infection (Tan et al. 2005; Wearing & Rohani 2009), decreased 
vaccination rates (Omer et al. 2009), variable vaccine efficacy (Crowcroft & Pebody 
2006; Ntezayabo et al. 2003), age-structured contact patterns (Rohani et al. 2010), 
acellular vaccines (first implemented in 1991) protect against disease but not infection 
and thus fail to prevent transmission (Warfel & Merkel 2012), and antigenic divergence 
of circulating strains in response to selective pressures from vaccines (Mooi et al. 2001; 
Mooi et al. 2009; Marieke J. Bart et al. 2014; Bart et al. 2010).  Evidence for these 
hypotheses has been reviewed elsewhere (Sealey et al. 2016; Burns et al. 2014). 
This study will address the extent to which the current resurgence in reported 
cases in the United States can be explained by genetic variation in circulating strains in 
response to selective pressure from vaccines. 
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5.2.1 Vaccine Composition 
The whole cell pertussis vaccine, first introduced in the United States in the 
1940’s was generally composed of 1-3 different strains, which varied between 
manufacturers and were selected from the predominant circulating types (Guiso 2009; 
Schmidtke et al. 2012).  It is unclear specifically which strains were used.  Due to 
concerns over reactogenicity of the whole cell vaccine, an acellular vaccine was 
introduced in the United States in 1991 as a safer alternative (Centers for Disease 
Control and Prevention 2016). 
 The current acellular pertussis vaccines contain five B. pertussis components:  
pertussis toxin (PT), filamentous hemagglutinin (FHA), fimbrial agglutinogens 2 and 3 
(FIM2 and FIM3), and pertactin (PRN) (Decker & Edwards 2000).  The two main 
manufacturers of the acellular vaccine used in the United States are GlaxoSmithKline 
and Sanofi Pasteur.  The strain used for the manufacture of the GlaxoSmithKline vaccine 
in the United States is Tohama 1, a strain first isolated in Japan, which has an allelic 
variant profile of prn (1)-ptxP(1)-ptxS1B-fim2(1)-fim3(A) (Schmidtke et al. 2012; Bottero 
et al. 2007). The Sanofi Pasteur acellular pertussis vaccine is manufactured from B. 
pertussis strain 10536 (prn(1)-ptxP(1)-ptxS1D-fim2(1)-fim3(A))(Bottero et al. 
2012)obtained from the Michigan Department of Health (Grabenstein 2012).  Studies 
worldwide document antigenic divergence between vaccine strains and currently 
circulating isolates with respect to several of these surface proteins (Schmidtke et al. 
2012; Cassiday et al. 2000; Kallonen & He 2009; Octavia et al. 2012; Advani et al. 2011; 
Bart et al. 2010; Borisova et al. 2007; Mooi et al. 1998).  The main components of these 
acellular vaccines and the current predominately circulating allele in the United States 
are listed below (Table 5.1). 
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Table 5.1  Genotype of vaccine strains, number of circulating alleles, and predominant 
allele in United States. 
 prn ptxP ptxS1 fim2 fim3 Sources 
Tohama 1 genotype 1 1 B 1 A 
Schmidtke et al. 
2012 
Bottero et al. 2012 
10536 genotype 1 1 D 1 A 
Bottero et al. 2012 
Grabenstein 2012 
Number of circulating 
alleles 
2 11 6 2 4 
Kallonen and He 
2009 
Mooi et al. 2009 
Locht 2007 
Predominate allele in 
US 
2 3 A  B 
Schmidtke et al. 
2012 
Cassiday 2000 
 
5.2.2 Pertussis Particularly Susceptible to Vaccine-Induced Selection 
Diseases like pertussis can be particularly susceptible to vaccine-induced 
selection because the acellular vaccine may not be completely effective at blocking 
transmission and there is an abundance of evidence that immunity wanes within a few 
years of vaccination creating leaky hosts (Warfel et al. 2014; Klein et al. 2012; Tartof et 
al. 2013; Mooi 2010; Read & Mackinnon 2007).  When a vaccine fails to induce sterilizing 
immunity, natural selection has the opportunity to act on wildtype pathogens as they 
pass through vaccinated hosts allowing identification of weakness in vaccine-induced 
immunity (Read & Mackinnon 2007).  In addition, the acellular vaccines only target 3-5 
pathogen antigens (Read & Mackinnon 2007).  By only targeting a subset of strains 
within a population, variants not included in the vaccine are given a competitive 
advantage (Read & Mackinnon 2007).  Even without strain-specific effects, wide-spread 
vaccination reduces the number of hosts who are fully susceptible within a population 
thereby reducing the probability that B. pertussis will encounter and be amplified in a 
susceptible host.  This dependency on the immune status of the host in determination 
of relative pathogen fitness also prompts pathogen evolution through variable selection 
(Read & Mackinnon 2007).  While the mutations occur at random, selective pressures 
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can increase the frequency of advantageous mutations.  When mutations arise in the 
surface antigens to which the vaccine has induced protective immunity against, the 
encoded protein structure may differ so greatly that it is not recognizable by the host 
immune system creating a vaccine-escape mutant (Read & Mackinnon 2007).  Even 
under strong selection, advantageous mutations can go undetected within a population 
for decades before the balance is tipped in favor of vaccine-escape mutants (Read & 
Mackinnon 2007).  The presence of vaccine-escape mutants fits with the epidemiologic 
profile of B. pertussis; in 2015 86% of pertussis cases under age 7 with known 
vaccination status had received at least one dose of vaccine (Centers for Disease Control 
and Prevention 2016). 
5.2.3 Evidence for vaccine-driven evolution 
Pertussis toxin (ptxP1 allele) is a component of all acellular vaccines.  The ptxP3 
allele was first identified in the United States in 1989 and since 1991 has been the 
dominant ptxP allele in the United States replacing the ptxP1 allele found in both of the 
vaccine strains (Schmidtke et al. 2012).  The ptxP3 allele is associated with increased 
toxin production (Schmidtke et al. 2012; Mooi et al. 2009).   Bart et al. examined the 
sequences of 343 B. pertussis strains that were collected from around the world during 
1920-2010 and found that introduction of the acellular vaccine coincided with an 
expansion of the ptxP3 lineage resulting from the acquisition of the fim3–2 allele and 
with the decline of the ptxA1 carrying lineage (Marieke J. Bart et al. 2014).  These results 
support a vaccine-induced bottleneck resulting in a reduction in diversity followed by an 
expansion of the ptxP3 genotype (Marieke J. Bart et al. 2014).   
 Pertactin, another component of acellular vaccines, is a surface adhesin involved 
in attachment of the bacterium to integrin proteins on the surface of ciliated epithelial 
cells in the nasopharynx (Halperin SA 2012).  A transition from the vaccine allele of prn1 
to prn2 as the dominate allele in the United States occurred during the early 1990’s 
(Schmidtke et al. 2012; Cassiday et al. 2000).  Recently there has been a dramatic 
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increase in the number of strains that do not express pertactin (prn), with large 
variation occurring between countries (Belcher & Preston 2015).  The increase in prn-
deficient strains seems to occur mainly in countries using the acellular vaccine.   A study 
in Finland identified 2/76 strains as prn-deficient (Barkoff et al. 2012).  In Japan 27% of 
121 strains (Otsuka et al. 2012), in Australia 30% of 320 strains (Lam et al. 2014), and in 
the United States approximately 50% of the strains were identified as prn-deficient 
(Pawloski et al. 2014).    In the global collection analyzed by Bart et al. (discussed above), 
no strains were found to be prn-deficient (Marieke J. Bart et al. 2014).  The majority of 
these strains were isolated before 2008, which may indicate that prn-deficiency has 
arisen more recently (Marieke J. Bart et al. 2014).  Those infected with Prn-deficient 
strains and those infected with prn-expressing strains have displayed no difference in 
clinical presentation (Martin et al. 2015).  Interestingly, those infected with a prn-
deficient strain were more likely to be fully-vaccinated suggesting there may be a 
selective advantage for this state in areas where acellular vaccination coverage is high 
(Martin et al. 2015).  In a study examining B. pertussis clearance in mice, prn-expressing 
strains were cleared more rapidly than prn-deficient strains which suggests a potential 
fitness advantage to prn-deficiency in hosts vaccinated with the acellular vaccine 
(Hegerle et al. 2014).       
 In a study of 100 United Kingdom B. pertussis isolates dating from 1920-2012, 
with particular emphasis on isolates from the 2012 outbreak, Sealey et al. provided 
evidence that the genes encoding the acellular vaccine antigens are evolving more 
rapidly than genes encoding other cell surface proteins, based on a significantly higher 
frequency of synonymous and non-synonymous SNPs in vaccine antigen-encoding genes 
compared with cell surface protein-encoding genes, in all of the vaccine eras including 
the pre-vaccine era (Sealey et al. 2015).  Even in the absence of vaccination, the immune 
response to these antigens likely creates selective pressure (Sealey et al. 2015).  
However, since the introduction of acellular vaccines, the acellular vaccine antigen-
encoding gene evolution rates have significantly increased, which suggests that selective 
pressure on these antigens has increased since introduction of acellular vaccines (Sealey 
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et al. 2015).  Bart et al. calculated SNP densities for different categories of genes and 
found that SNP densities were higher than the genome average in the “virulence” and 
“transport and binding” genes categories.  Being on the surface of the bacteria, these 
genes are more likely to be subjected to selection pressure by the immune system.  
The findings of these studies support the hypothesis of vaccine-induced 
divergent selection pressure on B. pertussis and that there are fitness advantages to 
certain genotypes under this pressure, specifically those genotypes that allow for 
vaccine escape (Belcher & Preston 2015).   In this paper we use whole genome 
sequencing on a collection of isolates dating from 1935 (pre-vaccine era) to 2013 
(current vaccination composition and schedule) to determine how selective pressures 
from vaccination may have influenced the evolution of B. pertussis with a specific focus 
on the USA.   
5.3  Methods 
 We selected one hundred B. pertussis isolates from the CDC, FDA, and from a 
2012 Washington outbreak for whole genome sequencing to better understand the 
effect of vaccination on the B. pertussis population.  The isolates, dating from 1935-
2013, were randomly selected by location and vaccination time period to try and 
maximize the diversity within our collection.  We also included an oversample of isolates 
from the Washington 2012 outbreak to better understand diversity within a single 
outbreak.   
5.3.1 Selection of Isolates 
5.3.1.1 Selection of CDC isolates: 
Isolates were selected from the CDC Schmidtke et al. collection (Schmidtke et al. 
2012) based on unique year and state isolated combinations. Isolates of the same year 
and state are likely to be from the same outbreak and are likely to be highly clonal 
(Mooi 2010).   This selection method identified 234 different isolates from 46 different 
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states plus the US Virgin Islands and St. Croix.  An additional 23 isolates were randomly 
selected from the Washington 2012 outbreak collection (Table 5.2).   
5.3.1.2 Selection of FDA isolates: 
All available pertussis isolates with information on isolation date were selected 
from the FDA’s collection of historic isolates.  Analysis was limited to isolates that could 
be grown from the lyophilized samples, included information on date isolated, and were 
isolated in the United States (n=15) (Table 5.2). 
5.3.1.3 Selection of MDCH isolates: 
All available isolates from Michigan Department of Community Health (MDCH) 
were obtained (n=4) (Table 5.2). 
5.3.1.4 Selection of Washington isolates: 
The 2012 Washington outbreak collection contained 234 isolates.  Ten percent of 
this collection (23 isolates) were randomly selected and included in this study (Table 
5.2). 
5.3.2 Sampling of isolates for whole genome sequencing: 
Funding was available to sequence 100 of the isolates.  Our selection of isolates 
for sequencing was a follows. Isolates were first stratified by time period following the 
scheme proposed by Schmidtke et al:  period 1 (pre-vaccine era) 1935-1945, period 2 
(early whole cell vaccine era) 1946-1969, period 3 (late whole cell vaccine era) 1970-
1990, period 4 (combination of whole cell vaccine and acellular vaccine for 4th and 5th 
doses) 1991-1996, period 5 (early acellular vaccine era) 1997-1999, period 6 (middle 
acellular vaccine era) 2000-2002, period 7 (late acellular vaccine era) 2003-2005, and 
period 8 (Tdap booster era) 2006-2013 (Figure 5.1) (Schmidtke et al. 2012).   All five 
isolates from period 1 were sequenced (both FDA and CDC isolates).  To reduce as much 
variation due to source as possible, we limited selection for the other time periods to 
isolates from CDC (including the WA isolates).  Ten isolates were randomly selected 
from periods 2-7 to provide adequate coverage of all time periods.  Thirty-five isolates 
were selected from period 8 for sequencing: 25 were a random sample from the time 
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period and an additional 10 were randomly selected from the Washington 2012 
outbreak to allow us to answer questions about diversity within a single outbreak (Table 
5.2).  A larger sample from period 8 allows for more in depth study of this most recent 
time period. 
Table 5.2  Vaccination time periods with number of isolates and source, 1953-2013 
 
 
 
 
 
 
 
 
 
Time 
Period 
Years Vaccine Era 
Number of Isolates 
Selected for 
Sequencing 
CDC FDA MDCH WA Total  
1 1935-1945 Pre-vaccine era 3 2   5 5 
2 1946-1969 Early whole cell vaccine era 16 2   18 10 
3 1970-1990 Late whole cell vaccine era 42 11   53 10 
4 1991-1996 
Combination of whole cell 
vaccine and acellular 
vaccine for 4th and 5th doses 
35    35 10 
5 1997-1999 Early acellular vaccine era 45    47 10 
6 2000-2002 Middle acellular vaccine era 34    34 10 
7 2003-2005 Late acellular vaccine era 28    28 10 
8 2006-2013 Tdap booster era 28  4 23 55 35 
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5.3.3 DNA extraction and purification: 
DNA was extracted using a QIAGEN (Venlo, Netherlands) DNeasy Blood & Tissue 
kit and the QIAcube automated DNA extraction system.  One hundred microliters of 
each sample was first incubated at 37°C with an 80 μL enzyme cocktail comprised of 
Promega cell lysis solution (Madison, WI, USA), lysozyme, mutanolysin, RNase A, and 
lysostaphin (Sigma Aldrich) in 22.5:4.5:1.125: 1.125:1 parts, respectively for 30 minutes. 
After extraction, DNA quantity and quality was measured using a Nanodrop 2000C 
spectrophotometer (Thermo Scientific, Waltham, MA, USA), a picogreen quantification 
assay, and agarose quantification against a Lambda HindIII ladder (New England 
Biolabs).  Extracted DNA was stored at −80°C.  
5.3.4 Library Preparation and Base Calling: 
Library preparation (conversion of genomic DNA into sequencer-ready 
fragments) and high-throughput DNA sequencing was conducted by the Center for 
Microbial Genetics and Genomics at Northern Arizona University.  Base calling and 
image analysis was completed using the Illumina System with at least 25X coverage.        
8 7 6 5 4 3 2 
1997 
Pre-vaccine 
era  
1991 
Whole cell 
vaccine  
Acellular 
vaccine  
2005 1945 1935 
Whole cell 
vaccine 
introduced 
Acellular 
vaccine 
licensed for all 
5 doses 
1969 2013 
Acellular vaccine 
licensed for 4th and 5th 
dose of vaccination 
series 
1999 2003 
Single dose acellular 
vaccine booster 
recommended for 
adolescents and adults 
1 
Figure 5.1  Timeline of vaccine introduction into the United States with key periods 
for changes in vaccine selection pressure 
Adolescent and 
adult Dtap 
booster 
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5.3.5 Quality Control: 
 In addition to the quality control provided by the Illumina manufacturer, 
FastQValidator was applied to check for errors, establish minimum read length, and 
examine deviation from expected GC content and the average phred quality per cycle 
and overall average quality 
(http://genome.sph.umich.edu.proxy.lib.umich.edu/wiki/FastQValidator). 
5.3.6 Alignment: 
Reads were aligned against the Bordetella pertussis Tohama 1 genome (Parkhill 
et al. 2003)  using the Burrows-Wheeler Aligner BWA-mem algorithm (available:  
http://bio-bwa.sourceforge.net/).  The resulting .sam files were converted to .bam files 
then sorted and indexed using samtools (Li et al. 2009).  The MarkDuplicates tool of 
Picard was used to identify and remove PCR optical duplicate reads originating from a 
single fragment of DNA that can occur during sample preparation 
(https://broadinstitute.github.io/picard/index.html).  The MarkDuplicates tool was used 
with REMOVE_DUPLICATES=True, CREATE_INDEX=true, and 
VALIDATION_STRINGENCY=lenient.   The Picard output was then indexed using Samtools  
(Li et al. 2009).   
5.3.7 Variant calling and filtration: 
Samtools mpileup (http://samtools.sourceforge.net/mpileup.shtml) was used 
to collect summary information from the input bam files.  It calculates the likelihood of 
data given each possible genotype then stores the results in BCF format.  The resulting 
BCF files were piped into Bcftools for variant calling 
(https://samtools.github.io/bcftools/bcftools.html#call).  The following options were 
selected for samtools mpileup:  -u (generates uncompressed output which is better for 
piping), -g (generates genotype likelihoods and output them bcf), and -f (indexed 
reference file is in FASTA format.  The following options were selected for Bcftools call:  -
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Ov (output type uncompressed vcf), -v (output variant sites only), -c (consensus-caller 
method), -o (specify output file). 
Variant filtering was conducted using the GATK -VariantFiltration tool 
(https://software.broadinstitute.org/gatk/guide/tooldocs/org_broadinstitute_gatk_tool
s_walkers_filters_VariantFiltration.php).   We used the --filterExpression argument with 
FQ<0.025 (consensus quality - positive indicates heterozygote, negative indicates 
homozygote.  In bacterial samples it provides evidence as to whether a particular gene 
was duplicated in the sample), MQ > 50 (Root mean square mapping quality is an 
estimate of the overall mapping quality of reads supporting a particular variant call), 
QUAL>100 (selects for phred-scaled quality score greater than 100), and DP>15 
(requires more than 15 to support a variant call at a given position).  Vcftools was used 
to remove indels and keep only the SNPs that passed the GATK filtering criteria 
(Danecek et al. 2011) 
5.3.8 Generation of consensus sequences and multi-alignment FASTA file 
After filtration and removal of indels, the VCF files were zipped and indexed with 
bzip (http://www.htslib.org/doc/tabix.html) and bcftools 
(https://samtools.github.io/bcftools/bcftools.html#index), respectively.  A consensus 
sequence for each B. pertussis isolate was generated by applying the filtered VCF files to 
the B. pertussis Tohama 1 reference FASTA files with the use of bcftools consensus 
(https://samtools.github.io/bcftools/bcftools.html#consensus).  Once the consensus 
sequences were generated, the headers were changed to reflect the isolate name and 
date rather than the referent name.  The consensus sequences were then concatenated 
to generate a single multi-alignment FASTA file.  Snp-sites was used to extract SNPs from 
the multi-alignment file (Keane et al. 2016) 
5.3.9 Annotation and Analysis 
SNPs were annotated using script provided by Yancy Lo.  A neighbor joining tree 
with 100 bootstrap replicates was created using Seaview.  Invariable sites and across 
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site variation were both set to “none”.  Default parameters were used for Tree 
searching operations and Starting tree (Gouy et al. 2010).  The tree was then uploaded 
into iTOL, midpoint rooted, and color-coded by vaccine era (Letunic & Bork 2016). 
A pairwise distance matrix was created with the ape package in R (http://ape-
package.ird.fr/).   Histograms of SNP locations and pairwise distances were also created 
using R.  Further analysis of branch length and pairwise distance by vaccination period 
was conducted using SAS software version 9.4 (SAS Institute, Cary, NC).  The corr 
procedure was used to assess correlation between branch length and isolation date and 
pairwise distance from FDA-2 and isolation date.  ANOVA was used to detect overall 
differences in branch length or pairwise distance by vaccination period and the tukey 
test to assess specifically which vaccination periods differed from one another.  Analyses 
were conducted with and without the FDA-2 isolate as it was an outlier in the analyses 
and strongly influenced the results. 
 This project (HUM00052197) received exempt status from the University of 
Michigan Institutional Review Board on June 27, 2011.   
 
5.4 Preliminary Results  
Of the 100 B. pertussis isolates sent for whole genome sequences, 93 produced 
high-quality sequences that could be used in the analyses.  One isolated from period 6 
(Middle Acellular Vaccine Era), 1 isolate from period 7 (late acellular vaccine era), and 5 
isolates from period 8 (Tdap booster era) were excluded from the analysis due to 
absence of usable sequence data. 
The phylogeny revealed 2 main clades similar to the phylogeny produced by a 
global collection of 343 strains isolated between 1920 and 2010 (Figure 5.3) (Marieke J. 
Bart et al. 2014).  There was a distinct separation between the pre-vaccine era isolates 
and the rest of the collection (p<0.0001).  These results support a significant effect of 
vaccination on extinction of strains resulting in a replacement of populations.  
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Many of the smaller clades had low bootstrap values indicating little support for 
evolutionary relationships between strains.  All pre-vaccine strains were in clades that 
contained no post-vaccine strains.   
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Figure 5.2  Neighbor-joining tree with 100 bootstrap replicates. Color shading 
represents vaccine time period.  The branch length depicted in the legend represents 
an average of 0.1 nucleotide substitutions per site. 
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We found 3,018 SNPs between this collection and the Tohama 1 reference 
genome.  Similarly Bart et al. found limited genetic diversity in their collection, 
identifying only 5414 SNPs and an average SNP density of 0.0013 SNPs/bp (Marieke J. 
Bart et al. 2014).  There did not appear to be any hot spots in the genome for 
substitution (Figure 5.3).   
 
Figure 5.3  Count of SNPS per genome region from multi-sequence alignment 
 
 
Since the introduction of vaccination, the diversity between strains has reduced.  
The average pairwise difference between strains during the pre-vaccine era was 0.01 
(range: 0.01-0.02) and decreased to an average of 0.0007 (range:  0.0007-0.1) after the 
introduction of vaccination indicating a smaller population size.  Vaccination likely 
created a genetic bottleneck, where a very small subset of the population survived.  This 
is contrary to findings in a global collection of B. pertussis isolates which found no loss in 
diversity following the introduction of vaccination (Marieke J. Bart et al. 2014).   
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However, studies in more globally restricted populations, such as ours, also observed a 
decrease in population diversity after introduction of vaccination as would be expected 
if selective pressure from vaccination resulted in a population bottleneck where strains 
immune to the vaccine are more likely to survive (Litt et al. 2009; Van Loo & Mooi 2002; 
Weber et al. 2001). 
In the histogram of pairwise distances for all isolates, there are three bars; the 
largest is at the smallest pairwise distance because the post-vaccine era isolates are so 
similar to one another (Figure 5.4).  The second largest bar was also at a very small 
pairwise difference, because although the pre-vaccine era isolates were distinctly 
clustered from the post-vaccine era isolates they were still highly similar.  The largest 
pairwise differences were the distances of all the isolates from FDA-2, a pre-vaccine era 
isolate. 
Additional analyses, as outlined below, are needed to explore the effect of 
acellular vaccination on the B. pertussis population, characterize diversity within a single 
outbreak, and to explore the possibility of asymptomatic carriage as a major reservoir of 
pertussis infection. 
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Figure 5.4  Count of isolates for each pairwise distance by pre-vaccine and post-
vaccine era 
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5.5 Future Analyses 
5.5.1 Re-align to closed genome to explore genome rearrangement in our strains 
 The first task will be to re-align the reads from our strains to a closed, ordered 
genome that was created using a combination of long-read sequencing and restriction 
optical mapping.  This will give us a better picture of the presentation and variation in 
location of insertion sequence elements.  The majority of B. pertussis sequences 
generated so far were created with the use of Illumina short-read sequencing, which 
creates reads that are not long enough to span the 1kb IS481 repeat regions making it 
impossible to create a closed, ordered genome sequence from the data (Belcher & 
Preston 2015).  With the introduction of long-read sequence platforms, it is now 
possible to generate long-range scaffolds and create closed genome sequences (Liao et 
al. 2015).  A study of 31 statewide epidemic strains and 2 re-sequenced vaccine strains 
combined short- and long-read sequencing platforms with restriction optical mapping to 
create a closed genome de novo assembly.  Using this method, they were able to 
identify 16 distinct genome rearrangement profiles among the epidemic strains, all of 
which were distinct from the vaccine isolates (Bowden et al. 2016).  More copies of 
IS481 were also identified in the majority of epidemic strains as compared with the 
vaccine strains indicating that gene inactivation by insertion of IS481 may be an 
important method for allowing B. pertussis to evade acellular vaccine-induced immunity 
in the host (Bowden et al. 2016). As further evidence, an IS481 was found within the prn 
gene locus in the majority of prn-deficient strains in the U.S. (Pawloski et al. 2014; 
Bowden et al. 2014).  Closed genomes were also assembled for two Dutch strains with 
three large inversions identified between the strains suggesting the potential for 
extensive variation in genome arrangement among B. pertussis strains (Marieke J Bart et 
al. 2014; Belcher & Preston 2015).  Given the apparent importance of genome 
rearrangement as a source of variation between B. pertussis strains, alignment to a 
closed genome will allow us to explore this in our strains.  For example, if we identify 
prn-deficiency in our strains, is it due to an insertion of IS481? 
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5.5.2 Identify temporal trends in strain frequencies for vaccine antigen alleles  
 Studies worldwide document divergence between vaccine strains and currently 
circulating strains with respect to the antigens contained in the acellular vaccines 
(Schmidtke et al. 2012; Cassiday et al. 2000; Kallonen & He 2009; Octavia et al. 2012; 
Advani et al. 2011; Bart et al. 2010; Borisova et al. 2007; Mooi et al. 1998).  To assess 
how vaccination may have affected our B. pertussis population, we will assess the strain 
frequencies for each of the acellular vaccine antigen (fim2, fim3, ptxA, ptxP, prn) alleles 
by the eight vaccination time periods outlined.  This will allow us to determine if any 
allele shifts over time, such as the ptxP1 to ptxP3 identified by Bart et al. can be 
observed in our collection (Marieke J. Bart et al. 2014). 
5.5.3 Further Characterize Identified SNPs and Calculate SNP Densities and Mutation 
Rates in Regions of Interest 
 We will classify the SNPs identified as non-coding, synonymous, or non-
synonymous.  A synonymous SNP is one that changes the codon to a different codon 
which codes for the same amino acid while a non-synonymous SNP codes for a different 
amino acid.  Exploring the synonymous versus non-synonymous mutation rate in regions 
of interest, such as the antigen encoding genes, will provide information as to whether 
selection is acting on that particular region.  The non-synonymous mutations can be 
further explored by identifying the functional classification of the predicted protein 
categories using a database of functional annotation such as EggNOG 4.5 (Huerta-Cepas 
et al. 2016).  Studies in a global collection of B. pertussis isolates and a collection of 
isolates from two statewide outbreaks in the United States both found an 
overrepresentation of non-synonymous SNPS in transport proteins which may suggest 
this as a method of adaption to vaccination (Marieke J. Bart et al. 2014; Bowden et al. 
2016).  Whether particular gene categories are evolving faster than others can be 
explored by determining if the SNP densities in these regions of interest differ 
significantly from the overall SNP density of the genome as a whole.  SNP densities in 
the vaccine antigen-encoding genes will also be compared between eras to determine if 
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selection pressure has increased on these regions since the introduction of acellular 
vaccines. 
5.5.4   Further Study Outbreak Strains to Characterize Diversity Within a Single 
Outbreak 
 In a study of 100 United Kingdom B. pertussis isolates dating from 1920-2012, 
with particular emphasis on isolates from the 2012 outbreak, Sealey et al. showed that 
many distinct strains contributed to the 2012 outbreak and that it was not due to the 
emergence of a novel and more virulent clone or to the expansion of an individual 
lineage (Sealey et al. 2015).  They also found very little difference between outbreak 
strains and strains isolated during periods of low pertussis incidence (Sealey et al. 2015).  
Further analyses of our outbreak strains are needed to determine if there is evidence of 
clonal spread of an individual lineage or novel clone within the outbreak or if many 
strains contributed.   
5.5.5 Determine Whether Our Population of Strains Support Asymptomatic Cases as 
a Significant Reservoir for Infection 
In an analysis of 36 U.S. B. pertussis clinical isolates, Althouse and Scarpino found 
more genetic diversity in the bacterial population than could be explained by the 
observed number of infections without the possibility of asymptomatic carriage and that 
the time of changes in age-specific attack rates were consistent with asymptomatic 
transmission (Althouse & Scarpino 2015).  Seroprevalence studies suggest that many 
more people are infected with B. pertussis than actually present with disease (HUYGEN 
et al. 2014; RØNN et al. 2014; Scott et al. 2015). These studies suggest that B. pertussis 
is endemic in the population, but only causes disease in a fraction of those infected 
(Belcher & Preston 2015).  Preliminary analysis of our isolates suggests limited 
asymptomatic carriage in the pre-vaccine era although further analysis is needed to 
confirm this and to assess whether there is evidence to support a larger role of 
asymptomatic carriage since the introduction of the acellular vaccine.  Although all of 
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our isolates were recovered from symptomatic individuals, it would be interesting to 
obtain isolates from asymptomatic individuals to determine if they represent a separate 
lineage (Belcher & Preston 2015). 
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 Summary and Conclusions Chapter 6.
6.1 What I Learned From 5.5 Years as a PhD Student 
6.1.1 Collecting Data and Samples Takes Time and Lots of It 
 For this study, I gathered 275 B. pertussis isolates dating from 1935-2012, ten 
years of pertussis case report data from the California Department of Public Health, and 
case report data from Marin County Health and Human Services.   The isolates took over 
two years to obtain and came from the Food and Drug Administration (FDA), Centers for 
Disease and Prevention (CDC), Michigan Department of Community Health (MDCH), and 
Seattle Children’s Hospital.   
The FDA collection came about when my Co-Adviser ran into an FDA pertussis 
researcher at a conference who offered access to his collection.  Never underestimate 
the power of networking.  After months of emailing back and forth, I was finally granted 
access to drive out to Bethesda and dig through the samples in their freezers myself to 
select what I wanted.  As an interesting side note, I also learned how to ship infectious 
agents on dry ice.  The isolates from the CDC proved to be the most challenging to 
obtain and the ones nobody thought could be obtained.  From the time I first identified 
the collection in a journal article and contacted the author to when the isolates finally 
arrived in the lab, over two years had passed. On my part, it took persuasion, a proposal 
demonstrating that I had a good idea and the right people working with me to carry out 
the project, authorship agreements, and a few precious, pre-vaccine era samples that 
were not yet a part of their collection.  It also took months of back-and-forth between 
the legal departments at both institutions to work out the material transfer agreements.  
The other samples were a little easier; my contacts at the CDC connected me to a 
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contact at Seattle Children’s Hospital and my adviser connected me with a colleague 
and friend at MDCH who agreed to provide samples.  In between these successes, there 
were plenty of failures.  Not everyone I contacted was equally helpful or willing to share 
data and samples; however, most people were willing to help a genuinely interested 
and enthusiastic graduate student. 
 As a Marin County Epidemiologist before I returned to graduate school, I was 
able to obtain permission from the Public Health Officer to bring case report data with 
me for use on my dissertation.  The data from CDPH was a little more challenging to 
obtain and involved over a year of back-and-forth emails and phone calls, and IRB 
applications at both institutions.  It was important to keep in mind that these data 
requests create work for other people and that they also put considerable effort into 
the initial collection of data and samples.  Being gracious yet persistent with requests 
and offering acknowledgement of the work of others through promises of authorship 
was instrumental in getting the job done.  The most important lesson learned from this 
was to not underestimate the amount of time and effort required to find and obtain the 
appropriate data and specimens, and to not be afraid to reach out to other researchers 
in the field.  Most were happy to help out a graduate student. 
6.1.2 Projects Fail - Know When to Move On 
 I had great plans for the California case report data.  I was going to examine how 
community factors such as vaccination rates, health care utilization, poverty level, and 
education affected an individual’s probability of being infected.  I spent a great deal of 
effort merging the California data with data from the US Census, California Department 
of Finance, California Expanded California Kindergarten Retrospective Survey of 
vaccination status, and California Vital Statistics. I excitedly analyzed the data according 
to my plan and sought advice from other committee members and colleagues on an 
appropriate analytic strategy.  The problem was CDPH only releases data at the County 
level to protect the privacy of those infected.  There was too much variability within a 
single county to identify community factors that predicted pertussis infection.  I needed 
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geographically higher resolution data such as census tract level or smaller that would 
never be released to me.   It was difficult to fathom dropping a project that was 
supposed to be a significant portion of my dissertation and that took so much effort and 
time to set up.  My adviser matter-of-factly told me to cut bait and come up with an 
idea for a new project.  She was right; it was a waste to throw more time and energy at 
a project that wasn’t going to work. 
 Another failed project involved screening archival throat swabs from healthy 
individuals and individuals with influenza-like illness.  From everything I’d read on 
pertussis, I knew testing was typically done using nasopharyngeal swabs.  There might 
not be enough B. pertussis DNA in the throat to actually be detected.  If we found B. 
pertussis, it would not only be great to have a positive result but also good to know that 
it can be picked up with a throat swab rather than the slightly more invasive 
nasopharyngeal swab.  If we didn’t find B. pertussis, we wouldn’t know if it was because 
it truly wasn’t there or if we were simply unable to detect it.  I extracted the DNA, 
learned how to do qPCR, and started screening my samples.  After screening about half 
of the samples, I had not found any positives.  I quickly realized that the results would 
be meaningless.  Zero positive samples didn’t tell us anything, either none of the 
samples contained B. pertussis or we couldn’t detect it from the throat swabs.  I learned 
new laboratory skills in the process, but there was no use continuing with the project. 
6.1.3 Biological Variability Exists - Challenges in the Lab 
 Outside of specimen and data collection, the project that took up the most 
amount of time was creating a high-throughput method for assessing for coaggregation 
among bacterial species and applying this method to the study of B. pertussis 
interactions with nasopharyngeal commensals.  This was my first hands on experience 
with true biological variability.  I would see exciting results of coaggregation between B. 
pertussis and a commensal strain one day, and then nothing the next.  The same thing 
would even happen with my positive control strains that were well-documented in the 
literature as coaggregating strains.  I experimented with changing the media, growth 
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times, and pH.  I swapped coaggregation buffer for PCR-grade water and swapped the 
bacterial stock I was using for stock that had been passaged fewer times.  After more 
than 30 trials on some of my crosses, I could not figure out why sometimes my 
coaggregation assays would work and sometimes they didn't.  After some persuasion 
from my adviser, I finally presented my results at lab meeting.  No one was surprised by 
my inability to get consistent results and everyone was wondering why I kept repeating 
my experiments determined to do so.  It turns out that the species I was working with 
change phases and are known for being highly variable.  Presenting my results earlier 
would have saved a lot of time and frustration.  I was too concerned about having a 
completely finished project before presenting the results when I should have been 
seeking input from my colleagues throughout the project.  Luckily, experiencing all of 
the variability helped me design a high-throughput methodology that allows for multiple 
replicates of a particular pair under identical conditions so outside factors that influence 
coaggregation can be further studied.   
6.1.4 Working with Archival Specimens 
 I was excited to obtain a collection of nasopharyngeal swabs collected from 
healthy individuals that were collected as part of a former student’s dissertation work 
on S. pneumoniae and felt they would be perfect for coming up with a prevalence 
estimate of asymptomatic B. pertussis carriage in a population highly vaccinated with 
the whole cell vaccine.  Realizing that the samples were nearly a decade old and that 
there were no guarantees as to their current quality, I selected a random sample of 
isolates that the former student had identified as positive for S. pneumoniae based on 
culture and tried to duplicate her results using PCR.  Out of the ten presumptive positive 
samples that I screened, nine resulted in positive determination giving me the false 
impression that the rest of the samples would be viable.  I went ahead and extracted 
DNA from each of the samples and carried on with my experiment.  I screened all of the 
samples for B. pertussis and got halfway through screening for S. aureus, when it 
became obvious that I was obtaining prevalence estimates for S. aureus (zero positive 
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samples) that were not even close to estimates from the literature of 19.0% to 55.1% 
(Kluytmans et al. 1997).  It was clear that there was an issue with the archival samples.  
To prevent the wasted time, I should have put more time up front in screening more 
samples and made sure to screen samples from every freezer box.  Working with 
archival specimens can be highly informative as new project ideas and technologies 
come to light, but it extremely important to thoroughly screen the samples for quality 
and viability. 
6.1.5 It Takes a Village 
 During my final year of graduate school, I finally learned the importance of taking 
on undergraduate students to help with my projects.  Once I developed a particular 
repetitive aspect of my protocol, such as DNA extraction, PCR, or coaggregation assays, 
it made way more sense to train an undergraduate researcher to help with the work 
rather than to try and do it all myself.  I was able to develop a protocol and learn the 
skills necessary to carry it out, a student had the benefit of gaining research experience, 
and the project was completed much faster.  Providing training, delegating tasks, and 
overseeing the work of others are all important skills gained from allowing 
undergraduate researches to help with projects.  
 Seek input early on and throughout a project.  Presenting protocols while still in 
development and preliminary results can improve projects, get the work done faster, 
and might prevent failed projects.  Rather than re-inventing the wheel, seek guidance 
from your committee and other researchers in the field.  It’s not cheating, it’s efficient. 
6.1.6 Gaining an Incredible Skill Set 
 While some of my projects failed and others I wasn’t able to complete as much 
as I’d have liked too, I still gained an incredible skill set.  I learned laboratory skills such 
as DNA extraction, PCR, qPCR, and how to carry out a Picogreen DNA quantification 
assay.  I learned how to develop and troubleshoot protocols and work with numerous 
types of laboratory equipment such as a confocal microscope and a FlowCam device.  I 
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became competent in working with many different bacterial species.  Most importantly, 
I became competent and confident in learning new techniques and where and how to 
search for answers to my questions. 
 Outside of the lab, I became comfortable developing research questions and 
setting up a study that could answer those questions.  I could identify potential sources 
of bias and think of ways a project could be improved.  I became skilled at creating 
protocols that could obtain clear and consistent results between researchers and 
learned to develop a manuscript for a peer-reviewed journal. 
 For my genomics project, I was fortunate to be selected to attend a Working 
with Pathogen Genomes Workshop at the Wellcome Trust Sanger Institute.  Here I 
learned to use Unix and work with programs from the command line, map and assemble 
genetic sequence data, call SNPs and identify regions of difference between genomes, 
annotate genomes, and develop phylogenetic trees.  Working with big data, learning 
and troubleshooting new software, and blending software programs together to create 
a pipeline that carried out all of the necessary tasks proved to be extremely difficult, but 
I did it.  Unfortunately the learning curve on this project was so steep, I barely scratched 
the surface of the analyses I’d planned to do.  I was able to create a pipeline that 
worked, create a tree, and conduct some preliminary analysis.  I walked away with these 
skills and a better understanding of how genetic sequence data can be used to answer 
questions of epidemiologic importance. 
 Outside of my dissertation work, I was also given the opportunity to teach.  I 
gained experience in developing lesson plans, assignments, and tests; public speaking, 
working with a diverse group of students, and tailoring my instruction to meet the 
needs of my students. 
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6.2 Outstanding Issues and Future Directions for My B. pertussis Work 
6.2.1 High-throughput Method for Assessing Coaggregation Among Bacterial Species 
(Chapter 2) 
 Combining the high-throughput screening method with confocal microscopy and 
the FlowCam device opens the door for in-depth studies of aggregation and 
coaggregation among large panels of test strains.  These methods can be used to 
identify the factors that contribute to high variability in coaggregation assay and to 
determine if coaggregation occurs in other biological systems.   
6.2.2 Coaggregation between B. pertussis and NP commensals (Chapter 3) 
 Further study is needed to better understand how B. pertussis interacts with 
nasopharyngeal microbiota.  While we provided evidence that some interaction is 
occurring, we were unable to clearly identify the type of interaction. 
 A case-control study in which nasopharyngeal swabs are taken from those with 
and without B. pertussis would be useful to identify differences in the microbiota 
between the two groups.  DNA from the swabs could be extracted and sequenced to 
give an idea of community composition (Foxman & Rosenthal 2013).  The swabs could 
also be cultured to capture the specific strains that frequently co-occur with one 
another and ones that never do.  Our research on B. pertussis showed there can be 
considerable strain variation in type and extent of interactions observed.   
Further studies could be done to assess for coaggregation or interbacterial 
competition between strains.  B. pertussis contains several mechanisms, such as 
bacteriophages and a type IV secretion system for secreting pertussis toxin, which may 
be important for interaction with the host microbiota and the ability to colonize a host 
(Weyrich et al. 2014).  Understanding the interaction between B. pertussis and the host 
microbiota may have implications for control and treatment.  Weyrich et al. point out 
that susceptibility to colonization by B. pertussis may be increased by disruption to the 
resident microbiota of the nasal cavity and hypothesize that this may contribute to why 
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infants, without a mature nasal cavity microbiota, are more susceptible to pertussis 
infections than healthy adults (Weyrich et al. 2014).  If the microbiota is important for 
fighting off B. pertussis colonization, the administration of broad-spectrum antibiotics 
could potentially increase risk colonization and disease among infants (Weyrich et al. 
2014). 
6.2.3 Estimation of B. pertussis asymptomatic carriage rates and co-occurrence with 
NP commensals (Chapter 4) 
Understanding the prevalence of asymptomatic carriage is important for 
determining the role it plays in the transmission system.  A study of nasopharyngeal B. 
pertussis carriage in healthy people is warranted – although getting healthy people to 
submit to an NP swab poses a challenge.  DNA could be extracted from these swabs and 
sequenced to identify organisms present.  This would be much more efficient than using 
PCR to screen for selected organisms and would require no a priori list of organisms of 
interest.  As this method often can’t resolve below the genera level, a mix of untargeted 
and targeted screening would likely be necessary.  
6.2.4 Evolution of B. pertussis in response to vaccination (Chapter 5) 
We have barely scratched the surface in terms of what can be done with the B. 
pertussis sequences.  As the samples for sequencing included an oversample of isolates 
from a single 2010 outbreak in Seattle, Washington, we can further explore these 
sequences to better understand diversity within a single outbreak.   Additionally, given 
that we have an external clock (1935-2013) based on the isolation dates, we can 
estimate the molecular clock for B. pertussis.  The SNP annotation we created can be 
used to determine the presence of positive selection on gene regions throughout the 
genome and to identify gene regions that are highly conserved.  We can also determine 
if allele frequencies differ in gene regions that code for the antigens commonly found in 
vaccines compared with other gene regions to see if selective pressures differ by gene 
region.  Other regions of interest include the gene regions that code for adenylate 
cyclase, lipopolysaccharide endotoxin, dermonecrotic heat-labile toxin, tracheal cytoxin, 
 104 
 
the bvgAS locus, and various serotype specific agglutinogens and envelope proteins that 
may be important for virulence or immune escape and have demonstrated sequence 
variation (Packard 2004; Bart et al. 2010).   
Mooi et al. suggest that vaccination may have selected for strains that can 
transmit through vaccinated hosts more efficiently by delaying the immune response; 
vaccines effectively remove infants as a major factor in transmission, changing the 
ecology of B. pertussis.  We can explore this hypothesis by determining if any of the 
mutations we have identified could be involved in immune suppression (Mooi 2010).  
We can also determine how phylogenetic trees based on SNPs identified from whole 
genome sequences align with currently published predictions of B. pertussis genome 
evolution based on MLST patterns.  We can also compare the results of our analyses 
from mapping to the Tohama 1 reference genome with those from a de novo assembly 
and to a more recently published closed genome created with PacBio. 
6.3 Implications for pertussis intervention 
 In this dissertation we explored several mechanisms that may contribute to 
resurgence of B. pertussis in the United States:  interaction with nasopharyngeal 
microbiota, asymptomatic carriage, and divergence of circulating strains from vaccine 
strains.  Understanding how B. pertussis interacts with the host microbiota may give 
insight into the sources of variation in risk of colonization given exposure, particularly 
considering that so many pertussis cases occur in fully vaccinated individuals.  It may 
also explain why infants with an underdeveloped microbiota are more susceptible to 
infection (Weyrich et al. 2014).  Given recent evidence that acellular vaccines may 
protect against disease but not against colonization, a better understanding of the 
actual prevalence of asymptomatic carriage is important for assessing its role in 
transmission and for decision-making regarding pertussis control.  Lastly, understanding 
how B. pertussis evolves in response to vaccination is essential for developing vaccines 
with the most effective components and determining the best vaccination strategies. 
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